    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                               	        	                                                                                                                                                 <!DOCTYPE html><html><head><script id="f5_cspm">(function(){var f5_cspm={f5_p:'DMNEACEMJOHIBAMMJIFALAAKKFGOFCJFBHHGKIHNNKOBKEBMOONBNAIOMOHAMAMMMCHBCCJNNNGKKCNLAFJCBGMKPJJHMILMGBGJFEPJOJEMNMCGCAFBFDLGKPMBDFEM',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}return;}}catch(err){return;}setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}f5_cspm.go();}());</script>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - ACIPHEX- rabeprazole sodium tablet, delayed release  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "ACIPHEX- rabeprazole sodium tablet, delayed release <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">ACIPHEX- rabeprazole sodium tablet, delayed release <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AACIPHEX%2D%20Rabeprazole%20Sodium%20Tablet%2C%20Delayed%20Release%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D5d103551%2D978f%2D472a%2D9c62%2D51e6e4dea068%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=aciphex-6.jpg&setid=5d103551-978f-472a-9c62-51e6e4dea068" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=aciphex-6.jpg&setid=5d103551-978f-472a-9c62-51e6e4dea068" src="image.cfm?type=img&name=aciphex-6.jpg&setid=5d103551-978f-472a-9c62-51e6e4dea068" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                												                                                                                </ul>                                    </li>                                </ul>								                                </div>            								                                                                                                <div class="mod drug-photos">                                <h2><a>View Drug Photos</a></h2>                                                                    <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Codes:</a></strong>                                        <ul>                                        <li>                                            <ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        <li class="img drug-photo">                                                            	<p>62856-0243-30</p>                                                                                                                                                                                            	<a href="/rximage.nlm.nih.gov/image/images/gallery/original/62856-0243-30_NLMIMAGE10_BB39DD9E.jpg"                                                                  class="thumbnail"                                                                  title="Rabeprazole&#x20;sodium&#x20;20&#x20;MG&#x20;Delayed&#x20;Release&#x20;Oral&#x20;Tablet&#x20;&#x5b;Aciphex&#x5d;"                                                                 data-slideorder="1"                                                                 data-ndccode="62856-0243-30"                                                                 data-standardname="Rabeprazole&#x20;sodium&#x20;20&#x20;MG&#x20;Delayed&#x20;Release&#x20;Oral&#x20;Tablet&#x20;&#x5b;Aciphex&#x5d;"                                                                 data-shape="ROUND"                                                                 data-size="8mm"                                                                 data-color="YELLOW"                                                                 data-scored="1"                                                                 data-imprint="ACIPHEX&#x3b;20"                                                                 data-photo-type="drug" >                                                                	<img id="zoom_2"                                                                         title="Rabeprazole&#x20;sodium&#x20;20&#x20;MG&#x20;Delayed&#x20;Release&#x20;Oral&#x20;Tablet&#x20;&#x5b;Aciphex&#x5d;"                                                                         alt="Rabeprazole&#x20;sodium&#x20;20&#x20;MG&#x20;Delayed&#x20;Release&#x20;Oral&#x20;Tablet&#x20;&#x5b;Aciphex&#x5d;"                                                                         data-zoom-image="//rximage.nlm.nih.gov/image/images/gallery/original/62856-0243-30_NLMIMAGE10_BB39DD9E.jpg"                                                                         src="//rximage.nlm.nih.gov/image/images/gallery/original/62856-0243-30_NLMIMAGE10_BB39DD9E.jpg"                                                                         />                                                                    <span class="enlarge"></span>                                                                </a>                                                             </li>                                                                                                                                                                                                                                                                                                                                                                                                                      </ul>                                        </li>                                    </ul>                                	                                </div>                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22RABEPRAZOLE%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=RABEPRAZOLE" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=RABEPRAZOLE" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=RABEPRAZOLE[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=RABEPRAZOLE/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=RABEPRAZOLE/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=RABEPRAZOLE/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=RABEPRAZOLE[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD01212&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    62856-243-30,                                                                                                                                        	                                    62856-243-41,                                                                                                                                        	                                    62856-243-90                                                                                                                                                                        								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Eisai Inc.</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                           </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	12/14                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&amp;type=pdf&amp;name=5d103551-978f-472a-9c62-51e6e4dea068" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&amp;type=zip&amp;name=ACIPHEX">XML</a>                                                    </li>                                                                                                                                                            <li class="medguide">Medication Guide:                                                         <a href="dailymed/medguide.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068" target="_blank">HTML</a>                                                                                                            </li>                                                                                                        <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">    <span class="Bold">These highlights do not include all the information needed to use ACIPHEX safely and effectively. See full prescribing information for ACIPHEX.</span>    <br />    <span class="Bold">ACIPHEX<span class="Sup">&reg;</span> (rabeprazole sodium) Delayed-Release Tablets, for oral use</span>    <br />    <span class="Bold">ACIPHEX<span class="Sup">&reg;</span> Sprinkle™ (rabeprazole sodium) Delayed-Release Capsules, for oral use</span>    <br />    <span class="Bold">Initial U.S. Approval: 1999</span>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>RECENT MAJOR CHANGES</span> </h1>    <div>     <ul class="Disc">      <li> <p class="Highlighta">Contraindications (<a href="#LINK_5d66dc20-a855-4bae-8f0d-16728cb2d6de">4</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12/2014 </p> </li>      <li> <p class="Highlighta">Warnings and Precautions; Acute Interstitial Nephritis (<a href="#LINK_389718eb-2652-489f-b693-a21e265b963d">5.3</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12/2014 </p> </li>      <li> <p class="Highlighta">Warnings and Precautions; Cyanocobalamin (vitamin B-12) <br />Deficiency (<a href="#LINK_4c47fb76-a636-4737-a906-47a428e50bd8">5.4</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12/2014 </p> </li>     </ul>    </div>   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">ACIPHEX is a proton-pump inhibitor (PPI) indicated in adults for: </p>     <ul class="Disk">      <li>Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) (<a href="#LINK_56c9010f-da5d-4a62-8613-bf0345b48a4e">1.1</a>) </li>      <li>Maintenance of Healing of Erosive or Ulcerative GERD (<a href="#LINK_5a9ec925-6d5f-4b7b-b1a2-0d0205b74f67">1.2</a>) </li>      <li>Treatment of Symptomatic GERD (<a href="#LINK_0cac6b5e-c106-48bf-9b4b-6983390ab001">1.3</a>) </li>      <li>Healing of Duodenal Ulcers (<a href="#LINK_46e8398f-404c-4812-8513-46c7037d78b6">1.4</a>) </li>      <li> <span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of Duodenal Ulcer Recurrence (<a href="#LINK_c10239e2-0b55-4564-b84f-43d13864d032">1.5</a>) </li>      <li>Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome (<a href="#LINK_eda84e43-3520-40c1-b84e-ef89e2f58045">1.6</a>)</li>     </ul>     <p class="Highlighta">In adolescent patients 12&nbsp;years of age and older for: </p>     <ul class="Disk">      <li>Short-term treatment of Symptomatic GERD (<a href="#LINK_bea8d18b-500f-435c-8094-0ea41aed41c9">1.7</a>)</li>     </ul>     <p class="Highlighta">In pediatric patients 1 to 11&nbsp;years of age for: </p>     <ul class="Disk">      <li>Treatment of GERD (<a href="#LINK_ec5315f5-d8d7-40bc-9f8e-40d81c8fe745">1.8</a>)</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <p class="Highlighta">ACIPHEX Delayed-Release Tablets should be swallowed whole. The tablets should not be chewed, crushed, or split (<a href="#LINK_ad3b76c5-49f1-49b3-befe-3fbe2eee04ed">2.10</a>). </p>     <p class="Highlighta">ACIPHEX Sprinkle Delayed-Release Capsules should be opened and the granule contents sprinkled on a spoonful of soft food or liquid (e.g., applesauce). Whole dose should be taken within 15&nbsp;minutes of being sprinkled. The granules should not be chewed or crushed. Dose should be taken 30&nbsp;minutes before a meal (<a href="#LINK_ad3b76c5-49f1-49b3-befe-3fbe2eee04ed">2.10</a>). </p>     <table>      <colgroup>      <col />       <col />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule" colspan="2" valign="top"><span class="Bold">Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)</span> (<a href="#LINK_26016347-449b-4c4c-8bc9-94735628565a">2.1</a>) </td>       <td class="Botrule" valign="top">&nbsp;20&nbsp;mg once daily for 4 to 8 weeks</td>       </tr>       <tr>        <td class="Botrule" colspan="2" valign="top"><span class="Bold">Maintenance of Healing of Erosive or Ulcerative GERD</span> (<a href="#LINK_abee17e1-9887-4221-83cb-c1ce409db0b1">2.2</a>) <br />*studied for 12 months</td>       <td class="Botrule" valign="top">&nbsp;20&nbsp;mg once daily *</td>       </tr>       <tr>        <td class="Botrule" colspan="2" valign="top"><span class="Bold">Treatment of Symptomatic GERD in Adults</span> (<a href="#LINK_3f17af28-d6b4-4bae-96e2-066fd472a741">2.3</a>) </td>       <td class="Botrule" valign="top">&nbsp;20&nbsp;mg once daily for 4 weeks</td>       </tr>       <tr>        <td class="Botrule" colspan="2" valign="top"><span class="Bold">Healing of Duodenal Ulcers</span> (<a href="#LINK_16539052-75cd-49db-b335-6c96dbda10e8">2.4</a>) </td>       <td class="Botrule" valign="top">&nbsp;20&nbsp;mg once daily after morning meal for up to 4 weeks</td>       </tr>       <tr>        <td colspan="3" valign="top"><span class="Bold"><span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of Duodenal Ulcer Recurrence</span> (<a href="#LINK_4fae7c66-8189-420f-8612-6150417848c1">2.5</a>) </td>       </tr>       <tr>        <td class="Botrule" valign="top"><span class="Bold">Three Drug Regimen:</span> <br />ACIPHEX 20&nbsp;mg<br />Amoxicillin 1000&nbsp;mg<br />Clarithromycin 500&nbsp;mg </td>       <td class="Botrule" colspan="2"><span class="Italics">All three medications should be taken twice daily with morning and evening meals for 7&nbsp;days.</span></td>       </tr>       <tr>        <td class="Botrule" colspan="2" valign="top"><span class="Bold">Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome</span> (<a href="#LINK_537ffd77-0b6f-4f61-83a3-65f5f649147d">2.6</a>) </td>       <td class="Botrule" valign="top"> Starting dose 60&nbsp;mg once daily then adjust to patient needs </td>       </tr>       <tr>        <td class="Botrule" colspan="2" valign="top"><span class="Bold">Treatment of Symptomatic GERD in Adolescents 12&nbsp;Years of Age and Older</span> (<a href="#LINK_c471f22e-27c7-4f37-affe-13e17f1918d7">2.7</a>) </td>       <td class="Botrule" valign="top"> 20&nbsp;mg once daily for up to 8 weeks</td>       </tr>       <tr class="Last">        <td class="Botrule" colspan="2" valign="top"><span class="Bold">Treatment of GERD in 1- to 11-Years-Olds</span> (<a href="#LINK_c773d80a-2165-4728-8a12-176f970e38c7">2.8</a>) </td>       <td class="Botrule" valign="top"> Less than 15&nbsp;kg: 5&nbsp;mg once daily <span class="Italics">(with the option to increase to 10&nbsp;mg once daily)</span> <br />15&nbsp;kg or greater: 10&nbsp;mg once daily for up to 12 weeks</td>       </tr>      </tbody>     </table>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <ul class="Disk">      <li>Delayed-Release Tablets: 20&nbsp;mg (<a href="#LINK_5443c21c-b736-4d04-83ee-32bad0f0bb2e">3</a>)</li>      <li>Delayed-Release Capsules: 5&nbsp;mg and 10&nbsp;mg (<a href="#LINK_5443c21c-b736-4d04-83ee-32bad0f0bb2e">3</a>)</li>     </ul>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <ul class="Disk">      <li>History of hypersensitivity to rabeprazole (<a href="#LINK_5d66dc20-a855-4bae-8f0d-16728cb2d6de">4</a>)</li>     </ul>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <ul class="Disk">      <li>Symptomatic response to therapy with rabeprazole does not preclude the presence of gastric malignancy (<a href="#LINK_3e4b4221-dc75-4a68-ab66-89257d1b7ec1">5.1</a>).</li>      <li>Use with warfarin: Monitor for increases in INR and prothombin time (<a href="#LINK_b446e0b9-eeb4-462d-a09e-26cc6ca70e45">5.2</a>).</li>      <li>Acute interstitial nephritis has been observed in patients taking PPIs (<a href="#LINK_389718eb-2652-489f-b693-a21e265b963d">5.3</a>).</li>      <li>Cyanocobalamin (vitamin B-12) Deficiency:&nbsp; Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin (<a href="#LINK_4c47fb76-a636-4737-a906-47a428e50bd8">5.4</a>). </li>      <li>PPI therapy may be associated with increased risk of <span class="Italics">Clostridium difficile</span> associated diarrhea (<a href="#LINK_269ec7f5-ce7a-4374-ab63-8df125265326">5.5</a>).</li>      <li>Bone fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine (<a href="#LINK_8d25f408-aa0f-4e89-a261-aa0df9198c32">5.6</a>).</li>      <li>Hypomagnesemia has been reported rarely with prolonged treatment with PPIs (<a href="#LINK_18b888cc-5552-4353-98aa-00f37fd91fa9">5.7</a>).</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <ul class="Disk">      <li>In the adult studies (4 to 8&nbsp;weeks), adverse reactions that occurred at a rate greater than 2% and greater than placebo included pain, pharyngitis, flatulence, infection, and constipation (<a href="#LINK_e7ec2522-fe54-4933-9857-3719ac37299f">6.1</a>).</li>      <li>In studies of pediatric and adolescent patients (ages 1 to 16&nbsp;years, and up to 36&nbsp;weeks exposure) adverse reactions that occurred at a rate of ≥5% of patients included abdominal pain, diarrhea, and headache (<a href="#LINK_e7ec2522-fe54-4933-9857-3719ac37299f">6.1</a>).</li>     </ul>     <p class="Highlighta"> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at 1-888-274-2378 or FDA at 1-800-FDA-1088 or </span><span class="Bold"><span class="Italics">www.fda.gov/medwatch.</span></span> </p>    </div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <ul class="Disk">      <li>Increased INR and prothrombin times have been reported with concomitant use with warfarin. Patients need to be monitored (<a href="#LINK_abad39e5-293c-4c2b-a6ad-1882b20fa8e0">7.2</a>).</li>      <li>Rabeprazole has been shown to inhibit cyclosporine metabolism <span class="Italics">in&nbsp;vitro</span> (<a href="#LINK_56dddb9f-57f8-4817-ad3c-6ac693e600e6">7.3</a>).</li>      <li>ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts, digoxin, and mycophenolate mofetil) (<a href="#LINK_11b6de87-c53f-4eef-a822-cb7ab7decf98">7.4</a>).</li>      <li>ACIPHEX may reduce the plasma levels of atazanavir (<a href="#LINK_11b6de87-c53f-4eef-a822-cb7ab7decf98">7.4</a>).</li>      <li>Methotrexate: ACIPHEX may increase serum level of methotrexate (<a href="#LINK_56fa1f62-1dff-4adc-9a13-9655b47b00f1">7.7</a>).</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>USE IN SPECIFIC POPULATIONS</span> </h1>    <div>     <ul class="Disk">      <li> <p class="Highlighta">Pregnancy: Based on animal data, may cause fetal harm (<a href="#LINK_e9b453ba-174b-40d5-b7f1-12a5791bd238">8.1</a>). </p> </li>      <li> <p class="Highlighta">Studies conducted do not support the use of ACIPHEX or the treatment of GERD in pediatric patients younger than 1&nbsp;year of age (<a href="#LINK_4c0f43a6-1f88-4f79-a7ab-df1a60ea179c">8.4</a>). </p> </li>      <li>The safety and efficacy of ACIPHEX for the other adult indications have not been established for pediatric patients (<a href="#LINK_4c0f43a6-1f88-4f79-a7ab-df1a60ea179c">8.4</a>).</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div>    <div></div>    <div></div>    <div></div>   </div>   <div>    <div></div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>   <p class="HighlightsRevision">Revised: 12/2014</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a> </h1>   <h2> <a href="#section-1.1" class="toc"> 1.1 Healing of Erosive or Ulcerative GERD in Adults </a> </h2>   <h2> <a href="#section-1.2" class="toc"> 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults </a> </h2>   <h2> <a href="#section-1.3" class="toc">1.3 Treatment of Symptomatic GERD in Adults</a> </h2>   <h2> <a href="#section-1.4" class="toc"> 1.4 Healing of Duodenal Ulcers in Adults </a> </h2>   <h2> <a href="#section-1.5" class="toc">1.5 <span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults</a> </h2>   <h2> <a href="#section-1.6" class="toc"> 1.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults </a> </h2>   <h2> <a href="#section-1.7" class="toc"> 1.7 Short-term Treatment of Symptomatic GERD in Adolescent Patients 12&nbsp;Years of Age and Older </a> </h2>   <h2> <a href="#section-1.8" class="toc">1.8 Treatment of GERD in Pediatric Patients 1 to 11 Years of Age</a> </h2>   <h1> <a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a> </h1>   <h2> <a href="#section-2.1" class="toc"> 2.1 Healing of Erosive or Ulcerative GERD in Adults </a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults</a> </h2>   <h2> <a href="#section-2.3" class="toc">2.3 Treatment of Symptomatic GERD in Adults</a> </h2>   <h2> <a href="#section-2.4" class="toc"> 2.4 Healing of Duodenal Ulcers in Adults </a> </h2>   <h2> <a href="#section-2.5" class="toc">2.5 <span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults</a> </h2>   <h2> <a href="#section-2.6" class="toc"> 2.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults </a> </h2>   <h2> <a href="#section-2.7" class="toc"> 2.7 Short-term Treatment of Symptomatic GERD in Adolescent Patients 12&nbsp;Years of Age and Older </a> </h2>   <h2> <a href="#section-2.8" class="toc">2.8 Treatment of GERD in Pediatric Patients 1 to 11 Years of Age</a> </h2>   <h2> <a href="#section-2.9" class="toc">2.9 Elderly, Renal, and Hepatic Impaired Patients</a> </h2>   <h2> <a href="#section-2.10" class="toc">2.10 Administration Recommendations</a> </h2>   <h1> <a href="#section-3" class="toc"> 3 DOSAGE FORMS AND STRENGTHS </a> </h1>   <h1> <a href="#section-4" class="toc">4 CONTRAINDICATIONS</a> </h1>   <h1> <a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a> </h1>   <h2> <a href="#section-5.1" class="toc">5.1 Presence of Gastric Malignancy</a> </h2>   <h2> <a href="#section-5.2" class="toc"> 5.2 Concomitant Use with Warfarin </a> </h2>   <h2> <a href="#section-5.3" class="toc">5.3 Acute Interstitial Nephritis</a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 Cyanocobalamin (vitamin B-12) Deficiency</a> </h2>   <h2> <a href="#section-5.5" class="toc">5.5 <span class="Italics"> Clostridium difficile</span> Associated Diarrhea</a> </h2>   <h2> <a href="#section-5.6" class="toc">5.6 Bone Fracture</a> </h2>   <h2> <a href="#section-5.7" class="toc">5.7 Hypomagnesemia</a> </h2>   <h2> <a href="#section-5.8" class="toc">5.8 Concomitant Use of ACIPHEX with Methotrexate</a> </h2>   <h1> <a href="#section-6" class="toc">6 ADVERSE REACTIONS</a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a> </h2>   <h2> <a href="#section-6.2" class="toc"> 6.2 Postmarketing Experience </a> </h2>   <h1> <a href="#section-7" class="toc">7 DRUG INTERACTIONS</a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Drugs Metabolized by CYP450</a> </h2>   <h2> <a href="#section-7.2" class="toc"> 7.2 Warfarin </a> </h2>   <h2> <a href="#section-7.3" class="toc"> 7.3 Cyclosporine </a> </h2>   <h2> <a href="#section-7.4" class="toc">7.4 Compounds Dependent on Gastric pH for Absorption</a> </h2>   <h2> <a href="#section-7.5" class="toc"> 7.5 Drugs Metabolized by CYP2C19 </a> </h2>   <h2> <a href="#section-7.6" class="toc"> 7.6 Combined Administration with Clarithromycin </a> </h2>   <h2> <a href="#section-7.7" class="toc">7.7 Methotrexate</a> </h2>   <h2> <a href="#section-7.8" class="toc"> 7.8 Clopidogrel </a> </h2>   <h1> <a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy</a> </h2>   <h2> <a href="#section-8.2" class="toc"> 8.3 Nursing Mothers </a> </h2>   <h2> <a href="#section-8.3" class="toc">8.4 Pediatric Use</a> </h2>   <h2> <a href="#section-8.4" class="toc"> 8.5 Geriatric Use </a> </h2>   <h2> <a href="#section-8.5" class="toc"> 8.6 Gender </a> </h2>   <h1> <a href="#section-9" class="toc">10 OVERDOSAGE</a> </h1>   <h1> <a href="#section-10" class="toc">11 DESCRIPTION</a> </h1>   <h1> <a href="#section-11" class="toc"> 12 CLINICAL PHARMACOLOGY </a> </h1>   <h2> <a href="#section-11.1" class="toc"> 12.1 Mechanism of Action </a> </h2>   <h2> <a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a> </h2>   <h2> <a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a> </h2>   <h1> <a href="#section-12" class="toc"> 13 NONCLINICAL TOXICOLOGY </a> </h1>   <h2> <a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a> </h2>   <h2> <a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a> </h2>   <h1> <a href="#section-13" class="toc"> 14 CLINICAL STUDIES </a> </h1>   <h2> <a href="#section-13.1" class="toc">14.1 Healing of Erosive or Ulcerative GERD in Adults</a> </h2>   <h2> <a href="#section-13.2" class="toc">14.2 Long-term Maintenance of Healing of Erosive or Ulcerative GERD in Adults</a> </h2>   <h2> <a href="#section-13.3" class="toc">14.3 Treatment of Symptomatic GERD in Adults</a> </h2>   <h2> <a href="#section-13.4" class="toc">14.4 Healing of Duodenal Ulcers in Adults</a> </h2>   <h2> <a href="#section-13.5" class="toc">14.5 <span class="Italics">Helicobacter pylori</span> Eradication in Patients with Peptic Ulcer Disease or Symptomatic Non-Ulcer Disease in Adults</a> </h2>   <h2> <a href="#section-13.6" class="toc"> 14.6 Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults </a> </h2>   <h2> <a href="#section-13.7" class="toc">14.7 Pediatric GERD</a> </h2>   <h1> <a href="#section-14" class="toc"> 15 REFERENCES </a> </h1>   <h1> <a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a> </h1>   <h1> <a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a> </h1>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="LINK_2f28a750-ab50-4569-89f2-744ba291d7d8"></a>  <a name="section-1"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="LINK_56c9010f-da5d-4a62-8613-bf0345b48a4e"></a>   <a name="section-1.1"></a>    <p></p>    <h2> 1.1 Healing of Erosive or Ulcerative GERD in Adults </h2>    <p class="First">ACIPHEX is indicated for short-term (4 to 8&nbsp;weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8&nbsp;weeks of treatment, an additional 8-week course of ACIPHEX may be considered.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_5a9ec925-6d5f-4b7b-b1a2-0d0205b74f67"></a>   <a name="section-1.2"></a>    <p></p>    <h2> 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults </h2>    <p class="First">ACIPHEX is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12&nbsp;months.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_0cac6b5e-c106-48bf-9b4b-6983390ab001"></a>   <a name="section-1.3"></a>    <p></p>    <h2>1.3 Treatment of Symptomatic GERD in Adults</h2>    <p class="First">ACIPHEX is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_46e8398f-404c-4812-8513-46c7037d78b6"></a>   <a name="section-1.4"></a>    <p></p>    <h2> 1.4 Healing of Duodenal Ulcers in Adults </h2>    <p class="First">ACIPHEX is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_c10239e2-0b55-4564-b84f-43d13864d032"></a>   <a name="section-1.5"></a>    <p></p>    <h2>1.5 <span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults</h2>    <p class="First">ACIPHEX, in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with <span class="Italics">H.&nbsp;pylori</span> infection and duodenal ulcer disease (active or history within the past 5&nbsp;years) to eradicate <span class="Italics">H.&nbsp;pylori</span>. Eradication of <span class="Italics">H.&nbsp;pylori</span> has been shown to reduce the risk of duodenal ulcer recurrence [<span class="Italics">see Clinical Studies (<a href="#LINK_2ebde5d5-074e-4dd9-b7a5-5ae818765dd9">14.5</a>)</span> and <span class="Italics">Dosage and Administration (<a href="#LINK_4fae7c66-8189-420f-8612-6150417848c1">2.5</a>)</span>].</p>    <p>In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_8cc2ea1f-ec7e-4c36-b69e-d922d53c1173">12.2</a>)</span> and the clarithromycin package insert, <span class="Italics">Clinical Pharmacology (12.2)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_eda84e43-3520-40c1-b84e-ef89e2f58045"></a>   <a name="section-1.6"></a>    <p></p>    <h2> 1.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults </h2>    <p class="First">ACIPHEX is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_bea8d18b-500f-435c-8094-0ea41aed41c9"></a>   <a name="section-1.7"></a>    <p></p>    <h2> 1.7 Short-term Treatment of Symptomatic GERD in Adolescent Patients 12&nbsp;Years of Age and Older </h2>    <p class="First">ACIPHEX is indicated for the treatment of symptomatic GERD in adolescents 12&nbsp;years of age and above for up to 8&nbsp;weeks.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_ec5315f5-d8d7-40bc-9f8e-40d81c8fe745"></a>   <a name="section-1.8"></a>    <p></p>    <h2>1.8 Treatment of GERD in Pediatric Patients 1 to 11 Years of Age</h2>    <p class="First">ACIPHEX is indicated for treatment of GERD in children 1 to 11&nbsp;years of age for up to 12&nbsp;weeks.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="LINK_28d368dd-6f9b-42a5-a130-c9031d6bd37a"></a>  <a name="section-2"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="LINK_26016347-449b-4c4c-8bc9-94735628565a"></a>   <a name="section-2.1"></a>    <p></p>    <h2> 2.1 Healing of Erosive or Ulcerative GERD in Adults </h2>    <p class="First">The recommended adult oral dose is one ACIPHEX 20&nbsp;mg Delayed-Release tablet to be taken once daily for four to eight weeks [<span class="Italics">see Indications and Usage (<a href="#LINK_56c9010f-da5d-4a62-8613-bf0345b48a4e">1.1</a>)</span>]. For those patients who have not healed after 8&nbsp;weeks of treatment, an additional 8-week course of ACIPHEX may be considered.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_abee17e1-9887-4221-83cb-c1ce409db0b1"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults</h2>    <p class="First">The recommended adult oral dose is one ACIPHEX 20 mg Delayed-Release tablet to be taken once daily. Controlled studies do not extend beyond 12&nbsp;months [<span class="Italics">see </span><span class="Italics">Indications and Usage (<a href="#LINK_5a9ec925-6d5f-4b7b-b1a2-0d0205b74f67">1.2</a>)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_3f17af28-d6b4-4bae-96e2-066fd472a741"></a>   <a name="section-2.3"></a>    <p></p>    <h2>2.3 Treatment of Symptomatic GERD in Adults</h2>    <p class="First">The recommended adult oral dose is one ACIPHEX 20&nbsp;mg Delayed-Release tablet to be taken once daily for 4&nbsp;weeks [<span class="Italics">see Indications and Usage (<a href="#LINK_0cac6b5e-c106-48bf-9b4b-6983390ab001">1.3</a>)</span>]. If symptoms do not resolve completely after 4&nbsp;weeks, an additional course of treatment may be considered.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_16539052-75cd-49db-b335-6c96dbda10e8"></a>   <a name="section-2.4"></a>    <p></p>    <h2> 2.4 Healing of Duodenal Ulcers in Adults </h2>    <p class="First">The recommended adult oral dose is one ACIPHEX 20&nbsp;mg Delayed-Release tablet to be taken once daily after the morning meal for a period up to four weeks [<span class="Italics">see Indications and Usage (<a href="#LINK_c10239e2-0b55-4564-b84f-43d13864d032">1.5</a>)</span>]. Most patients with duodenal ulcer heal within four weeks. A few patients may require additional therapy to achieve healing.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_4fae7c66-8189-420f-8612-6150417848c1"></a>   <a name="section-2.5"></a>    <p></p>    <h2>2.5 <span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults</h2>    <div class="scrollingtable">    <table>      <caption>       <span> TABLE 1 THREE DRUG REGIMEN<span class="Sup">a</span></span>      </caption>      <colgroup>      <col width="33%" />       <col width="33%" />       <col width="33%" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="3">All three medications should be taken twice daily with the morning and evening meals.<br /> <span class="Sup">a</span>It is important that patients comply with the full 7-day regimen [<span class="Italics">see Clinical Studies (<a href="#LINK_2ebde5d5-074e-4dd9-b7a5-5ae818765dd9">14.5</a>)</span>]. </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule">ACIPHEX<br />Delayed-Release<br />Tablet </td>       <td class="Botrule Lrule Rrule Toprule" align="center">20&nbsp;mg </td>       <td class="Botrule Lrule Rrule Toprule" align="center">Twice Daily for 7&nbsp;Days </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule">Amoxicillin </td>       <td class="Botrule Lrule Rrule" align="center">1000&nbsp;mg </td>       <td class="Botrule Lrule Rrule" align="center">Twice Daily for 7&nbsp;Days </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule">Clarithromycin </td>       <td class="Botrule Lrule Rrule" align="center">500&nbsp;mg </td>       <td class="Botrule Lrule Rrule" align="center">Twice Daily for 7&nbsp;Days </td>       </tr>      </tbody>     </table>   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_537ffd77-0b6f-4f61-83a3-65f5f649147d"></a>   <a name="section-2.6"></a>    <p></p>    <h2> 2.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults </h2>    <p class="First">The dosage of ACIPHEX in patients with pathologic hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60&nbsp;mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100&nbsp;mg QD and 60&nbsp;mg BID have been administered. Some patients with Zollinger-Ellison syndrome have been treated continuously with ACIPHEX for up to one year.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_c471f22e-27c7-4f37-affe-13e17f1918d7"></a>   <a name="section-2.7"></a>    <p></p>    <h2> 2.7 Short-term Treatment of Symptomatic GERD in Adolescent Patients 12&nbsp;Years of Age and Older </h2>    <p class="First">The recommended oral dose for adolescents 12&nbsp;years of age and older is one 20&nbsp;mg Delayed-Release Tablet once daily for up to 8&nbsp;weeks [<span class="Italics">see Use in Specific Populations (<a href="#LINK_4c0f43a6-1f88-4f79-a7ab-df1a60ea179c">8.4</a>)</span> and <span class="Italics">Clinical Studies (<a href="#LINK_b43f20dc-7f62-4fbd-a34f-f0d238c27276">14.7</a>)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_c773d80a-2165-4728-8a12-176f970e38c7"></a>   <a name="section-2.8"></a>    <p></p>    <h2>2.8 Treatment of GERD in Pediatric Patients 1 to 11 Years of Age</h2>    <p class="First">The recommended dosage of ACIPHEX Sprinkle for pediatric patients 1 to 11&nbsp;years of age by body weight is:</p>    <ul class="Disk">     <li>Less than 15&nbsp;kg: 5&nbsp;mg once daily for up to 12&nbsp;weeks with the option to increase to 10&nbsp;mg if inadequate response [see Clinical Studies (<a href="#LINK_b43f20dc-7f62-4fbd-a34f-f0d238c27276">14.7</a>)].</li>     <li>15&nbsp;kg or more: 10&nbsp;mg once daily for up to 12&nbsp;weeks [see Clinical Studies (<a href="#LINK_b43f20dc-7f62-4fbd-a34f-f0d238c27276">14.7</a>)].</li>    </ul>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_cdbb60c8-8641-42cc-b8d9-88a2513a6959"></a>   <a name="section-2.9"></a>    <p></p>    <h2>2.9 Elderly, Renal, and Hepatic Impaired Patients</h2>    <p class="First">No dosage adjustment is necessary in elderly patients, in patients with renal disease, or in patients with mild to moderate hepatic impairment. Administration of rabeprazole to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Due to the lack of clinical data on rabeprazole in patients with severe hepatic impairment, caution should be exercised in those patients.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_ad3b76c5-49f1-49b3-befe-3fbe2eee04ed"></a>   <a name="section-2.10"></a>    <p></p>    <h2>2.10 Administration Recommendations</h2>    <div class="scrollingtable">    <table width="700px">      <caption>       <span>TABLE 2 ADMINSTRATION RECOMMENDATIONS</span>      </caption>      <colgroup>      <col width="25%" />       <col width="30%" />       <col width="45%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp; Formulation </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp; Population </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp; Instructions </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule Toprule" valign="top">&nbsp; Delayed-Release <br />&nbsp; Tablet </td>       <td class="Botrule Lrule Rrule Toprule" valign="top">Adults and adolescents 12&nbsp;years of age and older </td>       <td class="Botrule Lrule Rrule Toprule" valign="top">Swallow tablets whole. Do not chew, crush or split tablets.<br />Tablets can be taken with or without food. </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule Toprule" valign="top">&nbsp; Delayed-Release <br />&nbsp; Capsule </td>       <td class="Botrule Lrule Rrule Toprule" valign="top">Pediatric patients 1 to 11&nbsp;years of age </td>       <td class="Botrule Lrule Rrule Toprule" valign="top">The dose should be taken 30&nbsp;minutes before a meal.<br />The granules should not be chewed or crushed. Open capsule and sprinkle entire contents on a small amount of soft food (e.g. applesauce, fruit or vegetable based baby food, or yogurt) or empty contents into a small amount of liquid (e.g. infant formula, apple juice, or pediatric electrolyte solution). The whole dose should be taken within 15&nbsp;minutes of preparation.<br /> <br />Food or liquid should be at or below room temperature. Do not store mixture for future use. </td>       </tr>      </tbody>     </table>   </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="LINK_5443c21c-b736-4d04-83ee-32bad0f0bb2e"></a>  <a name="section-3"></a>   <p></p>    <p class="First">ACIPHEX Delayed-Release Tablets are provided in strength of 20&nbsp;mg.</p>   <p>ACIPHEX Sprinkle Delayed-Release Capsules are provided in strengths of 5 and 10&nbsp;mg. The 5&nbsp;mg strength is a transparent blue and opaque white No.&nbsp;2 capsule. The cap of the capsule is imprinted with &quot;↑&quot; and the body is imprinted with &quot;ACX 5mg&quot;. The 10&nbsp;mg strength is a transparent yellow and opaque white No.&nbsp;2 capsule. The cap of the capsule is imprinted with &quot;↑&quot; and the body is imprinted with &quot;ACX 10mg&quot;.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="LINK_5d66dc20-a855-4bae-8f0d-16728cb2d6de"></a>  <a name="section-4"></a>   <p></p>    <p class="First">ACIPHEX is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticaria [<span class="Italics">see Adverse Reactions (<a href="#LINK_490a113c-b4a7-41da-a195-78037bf46fce">6</a>)</span>].</p>   <p>For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with ACIPHEX, refer to the <span class="Italics">Contraindications</span> section of their package inserts.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="LINK_f6602c55-9ded-4404-8ada-61b801376b06"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="LINK_3e4b4221-dc75-4a68-ab66-89257d1b7ec1"></a>   <a name="section-5.1"></a>    <p></p>    <h2>5.1 Presence of Gastric Malignancy</h2>    <p class="First">Symptomatic response to therapy with rabeprazole does not preclude the presence of gastric malignancy.</p>    <p>Patients with healed GERD were treated for up to 40&nbsp;months with rabeprazole and monitored with serial gastric biopsies. Patients without <span class="Italics">H.&nbsp;pylori</span> infection (221 of 326&nbsp;patients) had no clinically important pathologic changes in the gastric mucosa. Patients with <span class="Italics">H.&nbsp;pylori</span> infection at baseline (105 of 326&nbsp;patients) had mild or moderate inflammation in the gastric body or mild inflammation in the gastric antrum. Patients with mild grades of infection or inflammation in the gastric body tended to change to moderate, whereas those graded moderate at baseline tended to remain stable. Patients with mild grades of infection or inflammation in the gastric antrum tended to remain stable. At baseline, 8% of patients had atrophy of glands in the gastric body and 15% had atrophy in the gastric antrum. At endpoint, 15% of patients had atrophy of glands in the gastric body and 11% had atrophy in the gastric antrum. Approximately 4% of patients had intestinal metaplasia at some point during follow-up, but no consistent changes were seen.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_b446e0b9-eeb4-462d-a09e-26cc6ca70e45"></a>   <a name="section-5.2"></a>    <p></p>    <h2> 5.2 Concomitant Use with Warfarin </h2>    <p class="First">Steady state interactions of rabeprazole and warfarin have not been adequately evaluated in patients. There have been reports of increased INR and prothrombin time in patients receiving a proton pump inhibitor and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with a proton pump inhibitor and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_389718eb-2652-489f-b693-a21e265b963d"></a>   <a name="section-5.3"></a>    <p></p>    <h2>5.3 Acute Interstitial Nephritis</h2>    <p class="First">Acute interstitial nephritis has been observed in patients taking PPIs including ACIPHEX. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue ACIPHEX if acute interstitial nephritis develops [<span class="Italics">see Contraindications (<a href="#LINK_5d66dc20-a855-4bae-8f0d-16728cb2d6de">4</a>)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_4c47fb76-a636-4737-a906-47a428e50bd8"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 Cyanocobalamin (vitamin B-12) Deficiency</h2>    <p class="First">Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B-12) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_269ec7f5-ce7a-4374-ab63-8df125265326"></a>   <a name="section-5.5"></a>    <p></p>    <h2>5.5 <span class="Italics"> Clostridium difficile</span> Associated Diarrhea</h2>    <p class="First">Published observational studies suggest that PPI therapy like ACIPHEX may be associated with an increased risk of <span class="Italics">Clostridium difficile</span> associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [<span class="Italics">see Adverse Reactions </span><span class="Italics">(<a href="#LINK_6d9cacec-7b54-46b1-b889-0876fa615f9d">6.2</a>)</span>].</p>    <p>Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.</p>    <p> <span class="Italics">Clostridium difficile </span>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with ACIPHEX, refer to <span class="Italics">Warnings </span>and <span class="Italics">Precautions </span>sections of those package inserts.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_8d25f408-aa0f-4e89-a261-aa0df9198c32"></a>   <a name="section-5.6"></a>    <p></p>    <h2>5.6 Bone Fracture</h2>    <p class="First">Several published observational studies in adults suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines [<span class="Italics">see</span><span class="Italics">Dosage and Administration (<a href="#LINK_28d368dd-6f9b-42a5-a130-c9031d6bd37a">2</a>)</span> and <span class="Italics">Adverse Reactions (<a href="#LINK_6d9cacec-7b54-46b1-b889-0876fa615f9d">6.2</a>)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_18b888cc-5552-4353-98aa-00f37fd91fa9"></a>   <a name="section-5.7"></a>    <p></p>    <h2>5.7 Hypomagnesemia</h2>    <p class="First">Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI. </p>    <p>For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), healthcare professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [<span class="Italics">see Adverse Reactions (<a href="#LINK_6d9cacec-7b54-46b1-b889-0876fa615f9d">6.2</a>)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_b1649ad7-9d9c-473c-a8e1-3fa3191683bf"></a>   <a name="section-5.8"></a>    <p></p>    <h2>5.8 Concomitant Use of ACIPHEX with Methotrexate</h2>    <p class="First">Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; <span class="Italics">see methotrexate prescribing information</span>) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients [<span class="Italics">see Drug Interactions (<a href="#LINK_56fa1f62-1dff-4adc-9a13-9655b47b00f1">7.7</a>)</span>].</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="LINK_490a113c-b4a7-41da-a195-78037bf46fce"></a>  <a name="section-6"></a>   <p></p>    <p class="First">Worldwide, over 2900&nbsp;patients have been treated with rabeprazole in Phase&nbsp;II-III clinical trials involving various dosages and durations of treatment.</p>   <p>Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_e7ec2522-fe54-4933-9857-3719ac37299f"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Clinical Studies Experience</h2>    <p class="First"> <span class="Bold">Adults<br /> </span>The data described below reflect exposure to ACIPHEX in 1064 adult patients exposed for up to 8&nbsp;weeks. The studies were primarily placebo- and active-controlled trials in adult patients with Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD), Duodenal Ulcers, and Gastric Ulcers. The population had a mean age of 53&nbsp;years (range 18-89&nbsp;years) and had a ratio of approximately 60% male: 40% female. The racial distribution was 86% Caucasian, 8% African American, 2% Asian, and 5% other. Most patients received either 10&nbsp;mg, 20&nbsp;mg, or 40&nbsp;mg/day of ACIPHEX.</p>    <p>An analysis of adverse reactions appearing in ≥2% of ACIPHEX patients (n=1064), and with a greater frequency than placebo (n=89) in controlled North American and European acute treatment trials, revealed the following adverse reactions: pain (3% vs. 1%), pharyngitis (3% vs. 2%), flatulence (3% vs. 1%), infection (2% vs. 1%), and constipation (2% vs. 1%).</p>    <p>Three long-term maintenance studies consisted of a total of 740 adult patients; at least 54% of adult patients were exposed to rabeprazole for 6&nbsp;months while at least 33% were exposed for 12&nbsp;months. Of the 740 adult patients, 247 (33%) and 241 (33%) patients received 10&nbsp;mg and 20&nbsp;mg of ACIPHEX, respectively, while 169 (23%) patients received placebo and 83 (11%) received omeprazole.</p>    <p>The safety profile of rabeprazole in the maintenance studies in adults was consistent with what was observed in the acute studies.</p>    <p>Other adverse reactions seen in controlled clinical trials, which do not meet the above criteria (≥2% of ACIPHEX-treated patients and greater than placebo) and for which there is a possibility of a causal relationship to rabeprazole, include the following: headache, abdominal pain, diarrhea, dry mouth, dizziness, peripheral edema, hepatic enzyme increase, hepatitis, hepatic encephalopathy, myalgia, and arthralgia.</p>    <p> <span class="Italics">Combination Treatment with Amoxicillin and Clarithromycin:</span> In clinical trials using combination therapy with rabeprazole plus amoxicillin and clarithromycin (RAC), no adverse reactions unique to this drug combination were observed. In the U.S. multicenter study, the most frequently reported drug related adverse reactions for patients who received RAC therapy for 7 or 10&nbsp;days were diarrhea (8% and 7%) and taste perversion (6% and 10%), respectively.</p>    <p>No clinically significant laboratory abnormalities particular to the drug combinations were observed.</p>    <p>For more information on adverse reactions or laboratory changes with amoxicillin or clarithromycin, refer to their respective package prescribing information, <span class="Italics">Adverse Reactions</span> section.</p>    <p> <span class="Bold">Pediatric<br /> </span>In a multicenter, open-label study of adolescent patients 12 to 16&nbsp;years of age with a clinical diagnosis of symptomatic GERD or endoscopically proven GERD, the adverse event profile was similar to that of adults. The adverse reactions reported without regard to relationship to ACIPHEX that occurred in ≥2% of 111&nbsp;patients were headache (9.9%), diarrhea (4.5%), nausea (4.5%), vomiting (3.6%), and abdominal pain (3.6%). The related reported adverse reactions that occurred in ≥2% of patients were headache (5.4%) and nausea (1.8%). There were no adverse reactions reported in this study that were not previously observed in adults.</p>    <p>In a two-part, randomized, multicenter, double-blind, parallel-group study, 127 pediatric patients 1 to 11&nbsp;years of age with endoscopically proven GERD received either 5&nbsp;mg or 10&nbsp;mg (&lt;15&nbsp;kg body weight) or 10&nbsp;mg or 20&nbsp;mg (≥15&nbsp;kg body weight) rabeprazole. In this study, some patients were exposed to rabeprazole for 36&nbsp;weeks. Adverse reactions that occurred in ≥5% of patients included abdominal pain (5%), diarrhea (5%), and headache (5%). There were no adverse reactions reported in this study that were not previously observed in trials of adolescents and adults.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_6d9cacec-7b54-46b1-b889-0876fa615f9d"></a>   <a name="section-6.2"></a>    <p></p>    <h2> 6.2 Postmarketing Experience </h2>    <p class="First">The following adverse reactions have been identified during post approval use of ACIPHEX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: sudden death; coma, hyperammonemia; jaundice; rhabdomyolysis; disorientation and delirium; anaphylaxis; angioedema; bullous and other drug eruptions of the skin; severe dermatologic reactions, including toxic epidermal necrolysis (some fatal), Stevens-Johnson syndrome, and erythema multiforme; interstitial pneumonia; interstitial nephritis; TSH elevations; bone fractures; hypomagnesemia and <span class="Italics">Clostridium difficile</span> associated diarrhea. In addition, agranulocytosis, hemolytic anemia, leukopenia, pancytopenia, and thrombocytopenia have been reported. Increases in prothrombin time/INR in patients treated with concomitant warfarin have been reported.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="LINK_b5e5ef82-2d6e-4992-b3c1-28060f71f3ab"></a>  <a name="section-7"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="LINK_f149c5da-b617-4336-aeef-72f48700e5f7"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Drugs Metabolized by CYP450</h2>    <p class="First">Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system. Studies in healthy subjects have shown that rabeprazole does not have clinically significant interactions with other drugs metabolized by the CYP450 system, such as warfarin and theophylline given as single oral doses, diazepam as a single intravenous dose, and phenytoin given as a single intravenous dose (with supplemental oral dosing). Steady state interactions of rabeprazole and other drugs metabolized by this enzyme system have not been studied in patients.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_abad39e5-293c-4c2b-a6ad-1882b20fa8e0"></a>   <a name="section-7.2"></a>    <p></p>    <h2> 7.2 Warfarin </h2>    <p class="First">There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including rabeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death [<span class="Italics">see Warnings and Precautions (<a href="#LINK_b446e0b9-eeb4-462d-a09e-26cc6ca70e45">5.2</a>)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_56dddb9f-57f8-4817-ad3c-6ac693e600e6"></a>   <a name="section-7.3"></a>    <p></p>    <h2> 7.3 Cyclosporine </h2>    <p class="First"> <span class="Italics">In&nbsp;vitro</span> incubations employing human liver microsomes indicated that rabeprazole inhibited cyclosporine metabolism with an IC<span class="Sub">50</span> of 62&nbsp;micromolar, a concentration that is over 50&nbsp;times higher than the C<span class="Sub">max</span> in healthy volunteers following 14&nbsp;days of dosing with 20&nbsp;mg of rabeprazole. This degree of inhibition is similar to that by omeprazole at equivalent concentrations.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_11b6de87-c53f-4eef-a822-cb7ab7decf98"></a>   <a name="section-7.4"></a>    <p></p>    <h2>7.4 Compounds Dependent on Gastric pH for Absorption</h2>    <p class="First">Due to its effects on gastric acid secretion, rabeprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with ACIPHEX.&nbsp; </p>    <p>Concomitant treatment with rabeprazole (20 mg daily) and ketoconazole in healthy subjects decreased the bioavailability of ketoconazole by 30% and increased the AUC and C<span class="Sub">max</span> for digoxin by 19% and 29%, respectively. Therefore, patients may need to be monitored when such drugs are taken concomitantly with rabeprazole. Co-administration of rabeprazole and antacids produced no clinically relevant changes in plasma rabeprazole concentrations.</p>    <p>Concomitant use of atazanavir and PPIs is not recommended. Co-administration of atazanavir with PPIs is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.</p>    <p>Co-administration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving PPIs and MMF. Use ACIPHEX with caution in transplant patients receiving MMF.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_b4deba5f-86f4-4927-a6c5-b45bdeabb4cb"></a>   <a name="section-7.5"></a>    <p></p>    <h2> 7.5 Drugs Metabolized by CYP2C19 </h2>    <p class="First">In a clinical study in Japan evaluating rabeprazole in adult patients categorized by CYP2C19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. This could be due to higher rabeprazole plasma levels in poor metabolizers. Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_38c5b0ff-cc56-46a3-850e-981ab91e80db"></a>   <a name="section-7.6"></a>    <p></p>    <h2> 7.6 Combined Administration with Clarithromycin </h2>    <p class="First">Combined administration consisting of rabeprazole, amoxicillin, and clarithromycin resulted in increases in plasma concentrations of rabeprazole and 14-hydroxyclarithromycin [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_e77f084a-2b81-444f-976e-0158612719d6">12.3</a>)</span>].</p>    <p>Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions due to drug interactions [<span class="Italics">see Warnings and Precautions in prescribing information for clarithromycin</span>]. Because of these drug interactions, clarithromycin is contraindicated for co-administration with certain drugs [<span class="Italics">see Contraindications in prescribing information for clarithromycin</span>] [<span class="Italics">see Drug Interactions in prescribing information for amoxicillin</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_56fa1f62-1dff-4adc-9a13-9655b47b00f1"></a>   <a name="section-7.7"></a>    <p></p>    <h2>7.7 Methotrexate</h2>    <p class="First">Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted [<span class="Italics">see Warnings and Precautions (<a href="#LINK_b1649ad7-9d9c-473c-a8e1-3fa3191683bf">5.8</a>)</span>].</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_48be26a3-d44d-4c87-b830-70e41c87ebef"></a>   <a name="section-7.8"></a>    <p></p>    <h2> 7.8 Clopidogrel </h2>    <p class="First">Concomitant administration of rabeprazole and clopidogrel in healthy subjects had no clinically meaningful effect on exposure to the active metabolite of clopidogrel [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_e77f084a-2b81-444f-976e-0158612719d6">12.3</a>)</span>]. No dose adjustment of clopidogrel is necessary when administered with an approved dose of ACIPHEX.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="LINK_3415e795-db62-45b8-88e6-1a74b2d852b8"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="LINK_e9b453ba-174b-40d5-b7f1-12a5791bd238"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy</h2>    <p class="First"> <span class="Bold">Pregnancy Category C</span> </p>    <p> <span class="Italics">Risk&nbsp; </span><span class="Italics">Summary</span> </p>    <p>There are no adequate and well-controlled studies with ACIPHEX in pregnant women. No evidence of teratogenicity was seen in animal reproduction studies with rabeprazole at 13 and 8 times the human exposure at the recommended dose for GERD, in rats and rabbits, respectively (see <span class="Italics">Animal Data</span>). Changes in bone morphology were observed in offspring of rats treated with oral doses of a different PPI through most of pregnancy and lactation <span class="Italics">(</span>see<span class="Italics"> Animal Data)</span>. Because of these findings, ACIPHEX should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>    <p> <span class="Italics">Animal Data</span> </p>    <p>Embryo-fetal developmental studies have been performed in rats at intravenous doses of rabeprazole up to 50 mg/kg/day (plasma AUC of 11.8&nbsp;&micro;g•hr/mL, about 13 times the human exposure at the recommended oral dose for GERD) and rabbits at intravenous doses up to 30 mg/kg/day (plasma AUC of 7.3 &micro;g•hr/mL, about 8 times the human exposure at the recommended oral dose for GERD) and have revealed no evidence of harm to the fetus due to rabeprazole. </p>    <p>Administration of rabeprazole to rats in late gestation and during lactation at an oral dose of 400 mg/kg/day (about 195 times the human oral dose based on mg/m<span class="Sup">2</span>) resulted in decreases in body weight gain of the pups.</p>    <p style="border-left:1px solid;">A pre- and postnatal developmental toxicity study in rats with additional endpoints to evaluate bone development was performed with a different PPI at about 3.4 to 57 times an oral human dose on a body surface area basis. &nbsp;Decreased femur length, width and thickness of cortical bone, decreased thickness of the tibial growth plate, and minimal to mild bone marrow hypocellularity were noted at doses of this PPI equal to or greater than 3.4 times an oral human dose on a body surface area basis. Physeal dysplasia in the femur was also observed in offspring after in utero and lactational exposure to the PPI at doses equal to or greater than 33.6 times an oral human dose on a body surface area basis. Effects on maternal bone were observed in pregnant and lactating rats in a pre- and postnatal toxicity study when the PPI was administered at oral doses of 3.4 to 57 times an oral human dose on a body surface area basis. <span class="XmChange">When rats were dosed from gestational day 7 through weaning on postnatal day 21, a statistically significant decrease in maternal femur weight of up to 14% (as compared to placebo treatment) was observed at doses equal to or greater than 33.6 times an oral human dose on a body surface area basis.</span> </p>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="LINK_48ac3b91-53a5-4d1e-a6b0-55e73cba7b35"></a>   <a name="section-8.2"></a>    <p></p>    <h2> 8.3 Nursing Mothers </h2>    <p class="First">It is not known if ACIPHEX is excreted in human milk; however, rabeprazole is present in rat milk. Because many drugs are excreted in milk, caution should be exercised when ACIPHEX is administered to a nursing woman.</p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="LINK_4c0f43a6-1f88-4f79-a7ab-df1a60ea179c"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.4 Pediatric Use</h2>    <p class="First"> <span class="Italics">Symptomatic GERD in Adolescent Patients Greater or Equal to 12&nbsp;Years of Age</span> </p>    <p>In a multicenter, randomized, open-label, parallel-group study, 111 adolescent patients 12 to 16&nbsp;years of age with a clinical diagnosis of symptomatic GERD, or suspected or endoscopically proven GERD, were randomized and treated with either ACIPHEX 10&nbsp;mg or ACIPHEX 20&nbsp;mg once daily for up to 8&nbsp;weeks for the evaluation of safety and efficacy. The adverse event profile in adolescent patients was similar to that of adults. The related reported adverse reactions that occurred in ≥2% of patients were headache (5.4%) and nausea (1.8%). There were no adverse reactions reported in these studies that were not previously observed in adults.</p>    <p> <span class="Italics">GERD in Pediatric Patients 1 to 11&nbsp;Years of Age</span> </p>    <p>The use of ACIPHEX for treatment of GERD in pediatric patients 1 to 11&nbsp;years of age is supported by a randomized, multicenter, double-blind clinical trial which evaluated two dose levels of rabeprazole in 127 pediatric patients with endoscopic and histologic evidence of GERD prior to study treatment. Dosing was determined by body weight: Patients weighing 6.0 to 14.9&nbsp;kg received either 5 or 10&nbsp;mg and those weighing 15.0&nbsp;kg or more received 10 or 20&nbsp;mg of ACIPHEX Sprinkle daily. After 12&nbsp;weeks of rabeprazole treatment, 81% of patients demonstrated esophageal mucosal healing on endoscopic assessment. In patients who had esophageal mucosal healing at 12&nbsp;weeks and elected to continue for 24&nbsp;more weeks of rabeprazole, 90% retained esophageal mucosal healing at 36&nbsp;weeks. No prespecified formal hypothesis testing for evaluation of efficacy was conducted. The absence of a placebo group does not allow assessment of sustained efficacy through 36&nbsp;weeks. There were no adverse reactions reported in this study that were not previously observed in adolescents or adults.</p>    <p> <span class="Italics">Symptomatic GERD in Infants 1 to 11&nbsp;Months of Age</span> </p>    <p>Studies conducted do not support the use of ACIPHEX Sprinkle for the treatment of GERD in pediatric patients younger than 1&nbsp;year of age.</p>    <p>In a randomized, multicenter, placebo-controlled withdrawal trial, infants 1 to 11&nbsp;months of age with a clinical diagnosis of symptomatic GERD, or suspected or endoscopically proven GERD, were treated up to 8&nbsp;weeks in two treatment periods. In the first treatment period (open-label), 344&nbsp;infants received 10&nbsp;mg of ACIPHEX Sprinkle for up to 3&nbsp;weeks. Infants with clinical response were then eligible to enter the second treatment period, which was double-blind and randomized. Two hundred sixty-eight infants were randomized to receive either placebo or 5&nbsp;mg or 10&nbsp;mg ACIPHEX Sprinkle.</p>    <p>This study did not demonstrate efficacy based on assessment of frequency of regurgitation and weight-for-age Z-score. Adverse reactions that occurred in ≥5% of patients in any treatment group and with a higher rate than placebo included pyrexia (7%) and increased serum gastrin levels (5%). There were no adverse reactions reported in this study that were not previously observed in adolescents and adults.</p>    <p> <span class="Italics">Neonates &lt;1&nbsp;Month and Preterm Infants &lt;44&nbsp;Weeks Corrected Gestational Age</span> </p>    <p>Use of ACIPHEX Sprinkle in neonates is strongly discouraged at this time for the treatment of GERD, based on the risk of prolonged acid suppression and lack of demonstrated safety and effectiveness in neonates.</p>    <p>Based on population pharmacokinetic analysis, the median (range) for the apparent clearance (CL/F) was 1.05&nbsp;L/h (0.0543-3.44&nbsp;L/h) in neonates and 4.46&nbsp;L/h (0.822-12.4&nbsp;L/h) in patients 1 to 11&nbsp;months of age following once daily administration of oral ACIPHEX Sprinkle.</p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="LINK_93834c41-64e1-415d-98e6-0e74ff226bf1"></a>   <a name="section-8.4"></a>    <p></p>    <h2> 8.5 Geriatric Use </h2>    <p class="First">Of the total number of subjects in clinical studies of ACIPHEX, 19% were 65&nbsp;years and over, while 4% were 75&nbsp;years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_6a797d37-ef00-4e3c-96fe-ba89c5779474"></a>   <a name="section-8.5"></a>    <p></p>    <h2> 8.6 Gender </h2>    <p class="First">Duodenal ulcer and erosive esophagitis healing rates in women are similar to those in men. Adverse reactions and laboratory test abnormalities in women occurred at rates similar to those in men.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="LINK_53dc9af7-2941-49ea-bfc2-94d2adcd0072"></a>  <a name="section-9"></a>   <p></p>    <p class="First"> <span class="Bold">Because strategies for the management of overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug.</span> There has been no experience with large overdoses with rabeprazole. Seven reports of accidental overdosage with rabeprazole have been received. The maximum reported overdose was 80&nbsp;mg. There were no clinical signs or symptoms associated with any reported overdose. Patients with Zollinger-Ellison syndrome have been treated with up to 120&nbsp;mg rabeprazole QD. No specific antidote for rabeprazole is known. Rabeprazole is extensively protein bound and is not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive.</p>   <p>Single oral doses of rabeprazole at 786&nbsp;mg/kg and 1024&nbsp;mg/kg were lethal to mice and rats, respectively. The single oral dose of 2000&nbsp;mg/kg was not lethal to dogs. The major symptoms of acute toxicity were hypoactivity, labored respiration, lateral or prone position, and convulsion in mice and rats and watery diarrhea, tremor, convulsion, and coma in dogs.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="LINK_0513c10e-971b-4099-b0ba-a1feddcbc653"></a>  <a name="section-10"></a>   <p></p>    <p class="First">The active ingredient in ACIPHEX (rabeprazole sodium) Delayed-Release Tablets and in ACIPHEX Sprinkle (rabeprazole sodium) Delayed-Release Capsules is rabeprazole sodium, which is a proton pump inhibitor. It is a substituted benzimidazole known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1<span class="Italics">H</span>-benzimidazole sodium salt. It has an empirical formula of C<span class="Sub">18</span>H<span class="Sub">20</span>N<span class="Sub">3</span>NaO<span class="Sub">3</span>S and a molecular weight of 381.42. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform, and ethyl acetate and insoluble in ether and n-hexane. The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural figure is:</p>   <p>FIGURE 1</p>   <div class="Figure">    <img src="image.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&name=aciphex%2D1%2Ejpg" alt="Figure 1" />  </div>   <p>ACIPHEX is available for oral administration as Delayed-Release, enteric-coated tablets containing 20&nbsp;mg of rabeprazole sodium. ACIPHEX Sprinkle is available for oral administration as 5&nbsp;mg and 10&nbsp;mg rabeprazole sodium Delayed-Release Capsules containing enteric coated granules.</p>   <p>Inactive ingredients of the 20&nbsp;mg tablet are carnauba wax, crospovidone, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium stearate, mannitol, propylene glycol, sodium hydroxide, sodium stearyl fumarate, talc, and titanium dioxide. Iron oxide yellow is the coloring agent for the tablet coating. Iron oxide red is the ink pigment.</p>   <p>ACIPHEX Sprinkle Delayed-Release Capsules contain granules of rabeprazole sodium in a hard hypromellose capsule. Inactive ingredients are colloidal silicon dioxide, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium oxide, magnesium stearate, mannitol, talc, titanium dioxide, carrageenan, potassium chloride, FD&amp;C Blue No.&nbsp;2 Aluminum Lake (in the 5&nbsp;mg capsule), FD&amp;C Yellow, No.&nbsp;6 (in the 10&nbsp;mg capsule), and gray printing ink.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="LINK_87d9b5e8-2688-4e96-8c36-d3c7a4b13898"></a>  <a name="section-11"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="LINK_2ca51755-4f7a-4684-8b33-3f01bff57d2f"></a>   <a name="section-11.1"></a>    <p></p>    <h2> 12.1 Mechanism of Action </h2>    <p class="First">Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H<span class="Sub">2</span>-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H<span class="Sup">+</span>, K<span class="Sup">+</span>ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion.</p>    <p>In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied <span class="Italics">in&nbsp;vitro</span>, rabeprazole is chemically activated at pH&nbsp;1.2 with a half-life of 78&nbsp;seconds. It inhibits acid transport in porcine gastric vesicles with a half-life of 90&nbsp;seconds.</p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="LINK_8cc2ea1f-ec7e-4c36-b69e-d922d53c1173"></a>   <a name="section-11.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics</h2>    <p class="First"> <span class="Underline">Antisecretory Activity</span> </p>    <p>The antisecretory effect begins within one hour after oral administration of 20&nbsp;mg ACIPHEX. The median inhibitory effect of ACIPHEX on 24-hour gastric acidity is 88% of maximal after the first dose. ACIPHEX 20&nbsp;mg inhibits basal and peptone meal-stimulated acid secretion versus placebo by 86% and 95%, respectively, and increases the percent of a 24-hour period that the gastric pH&gt;3 from 10% to 65% (see table below). This relatively prolonged pharmacodynamic action compared to the short pharmacokinetic half-life (1-2&nbsp;hours) reflects the sustained inactivation of the H<span class="Sup">+</span>, K<span class="Sup">+</span>ATPase.</p>    <div class="scrollingtable">    <table width="548px">      <caption>       <span> TABLE 3 GASTRIC ACID PARAMETERS ACIPHEX VERSUS PLACEBO AFTER 7&nbsp;DAYS OF ONCE DAILY DOSING </span>      </caption>      <colgroup>      <col width="50%" />       <col width="25%" />       <col width="25%" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="3">&nbsp; *(p&lt;0.01 versus placebo) </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp; Parameter </td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp; ACIPHEX <br />(20&nbsp;mg QD) </td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp; Placebo </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; Basal Acid Output (mmol/hr) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0.4* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 2.8 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; Stimulated Acid Output (mmol/hr) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0.6* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 13.3 </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" valign="top">&nbsp; % Time Gastric pH&gt;3 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 65* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 10 </td>       </tr>      </tbody>     </table>   </div>    <p>Compared to placebo, ACIPHEX, 10&nbsp;mg, 20&nbsp;mg, and 40&nbsp;mg, administered once daily for 7&nbsp;days significantly decreased intragastric acidity with all doses for each of four meal-related intervals and the 24-hour time period overall. In this study, there were no statistically significant differences between doses; however, there was a significant dose-related decrease in intragastric acidity. The ability of rabeprazole to cause a dose-related decrease in mean intragastric acidity is illustrated below. </p>    <div class="scrollingtable">    <table width="700px">      <caption>       <span>TABLE 4 AUC ACIDITY (MMOL•HR/L) ACIPHEX VERSUS PLACEBO ON DAY 7 OF ONCE DAILY DOSING (MEAN&plusmn;SD) </span>      </caption>      <colgroup>      <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="5">&nbsp; *(p&lt;0.001 versus placebo) </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Lrule Rrule Toprule">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center" colspan="4">&nbsp; Treatment </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="bottom">&nbsp; AUC <br />interval <br />(hrs) </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 10&nbsp;mg <br />RBP<br />(N=24) </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 20&nbsp;mg <br />RBP<br />(N=24) </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 40&nbsp;mg <br />RBP<br />(N=24) </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; Placebo<br />(N=24) </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; 08:00&nbsp;- 13:00 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 19.6&plusmn;21.5* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 12.9&plusmn;23* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 7.6&plusmn;14.7* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 91.1&plusmn;39.7 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; 13:00&nbsp;- 19:00 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 5.6&plusmn;9.7* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 8.3&plusmn;29.8* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 1.3&plusmn;5.2* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 95.5&plusmn;48.7 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; 19:00&nbsp;- 22:00 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0.1&plusmn;0.1* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0.1&plusmn;0.06* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0.0&plusmn;0.02* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 11.9&plusmn;12.5 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; 22:00&nbsp;- 08:00 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 129.2&plusmn;84* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 109.6&plusmn;67.2* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 76.9&plusmn;58.4* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 479.9&plusmn;165 </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" valign="top">&nbsp; AUC 0-24&nbsp;hours </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 155.5&plusmn;90.6* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 130.9&plusmn;81* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 85.8&plusmn;64.3* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 678.5&plusmn;216 </td>       </tr>      </tbody>     </table>   </div>    <p>After administration of 20&nbsp;mg ACIPHEX Tablets once daily for eight days, the mean percent of time that gastric pH&gt;3 or gastric pH&gt;4 after a single dose (Day&nbsp;1) and multiple doses (Day&nbsp;8) was significantly greater than placebo (see table below). The decrease in gastric acidity and the increase in gastric pH observed with 20&nbsp;mg ACIPHEX Tablets administered once daily for eight days were compared to the same parameters for placebo, as illustrated below: </p>    <div class="scrollingtable">    <table width="700px">      <caption>       <span>TABLE 5 GASTRIC ACID PARAMETERS ACIPHEX ONCE DAILY DOSING VERSUS PLACEBO ON DAY 1 AND DAY 8 </span>      </caption>      <colgroup>      <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="5"><span class="Sup">a</span>No inferential statistics conducted for this parameter.<br />*(p&lt;0.001 versus placebo)<br /> <span class="Sup">b</span>Gastric pH was measured every hour over a 24-hour period. </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Lrule Rrule Toprule">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">&nbsp; ACIPHEX<br />20&nbsp;mg QD </td>       <td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">&nbsp; Placebo </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="bottom">&nbsp; Parameter </td>       <td class="Botrule Lrule Rrule" align="center" valign="bottom">&nbsp; Day&nbsp;1 </td>       <td class="Botrule Lrule Rrule" align="center" valign="bottom">&nbsp; Day&nbsp;8 </td>       <td class="Botrule Lrule Rrule" align="center" valign="bottom">&nbsp; Day&nbsp;1 </td>       <td class="Botrule Lrule Rrule" align="center" valign="bottom">&nbsp; Day&nbsp;8 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule">&nbsp; Mean AUC<span class="Sub">0-24</span> Acidity </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 340.8* </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 176.9* </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 925.5 </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 862.4 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule">&nbsp; Median trough pH (23-hr)<span class="Sup">a</span></td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 3.77 </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 3.51 </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 1.27 </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 1.38 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule">&nbsp; % Time Gastric pH&gt;3<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 54.6* </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 68.7* </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 19.1 </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 21.7 </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule">&nbsp; % Time Gastric pH&gt;4<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 44.1* </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 60.3* </td>       <td class="Botrule Lrule Rrule">&nbsp; 7.6 </td>       <td class="Botrule Lrule Rrule" align="center">&nbsp; 11.0 </td>       </tr>      </tbody>     </table>   </div>    <p> <span class="Underline">Effects on Esophageal Acid Exposure</span> </p>    <p>In patients with gastroesophageal reflux disease (GERD) and moderate to severe esophageal acid exposure, ACIPHEX 20&nbsp;mg and 40&nbsp;mg Tablets per day decreased 24-hour esophageal acid exposure. After seven days of treatment, the percentage of time that esophageal pH&lt;4 decreased from baselines of 24.7% for 20&nbsp;mg and 23.7% for 40&nbsp;mg, to 5.1% and 2.0%, respectively. Normalization of 24-hour intraesophageal acid exposure was correlated to gastric pH&gt;4 for at least 35% of the 24-hour period; this level was achieved in 90% of subjects receiving ACIPHEX 20&nbsp;mg and in 100% of subjects receiving ACIPHEX 40&nbsp;mg. With ACIPHEX 20&nbsp;mg and 40&nbsp;mg per day, significant effects on gastric and esophageal pH were noted after one day of treatment, and more pronounced after seven days of treatment.</p>    <p> <span class="Underline">Effects on Serum Gastrin</span> </p>    <p>In patients given daily doses of ACIPHEX for up to eight weeks to treat ulcerative or erosive esophagitis and in patients treated for up to 52&nbsp;weeks to prevent recurrence of disease, the median fasting gastrin level increased in a dose-related manner. The group median values stayed within the normal range.</p>    <p>In a group of subjects treated daily with ACIPHEX 20&nbsp;mg tablets for 4&nbsp;weeks, a doubling of mean serum gastrin concentrations was observed. Approximately 35% of these treated subjects developed serum gastrin concentrations above the upper limit of normal. In a study of CYP2C19 genotyped subjects in Japan, poor metabolizers developed statistically significantly higher serum gastrin concentrations than extensive metabolizers.</p>    <p> <span class="Underline">Effects on Enterochromaffin-like (ECL) Cells</span> </p>    <p>Increased serum gastrin secondary to antisecretory agents stimulates proliferation of gastric ECL cells, which, over time, may result in ECL cell hyperplasia in rats and mice and gastric carcinoids in rats, especially in females [<span class="Italics">see Nonclinical Toxicology (<a href="#LINK_9f22718a-9334-4c3a-bc90-298ce3ecfd97">13.1</a>)</span>].</p>    <p>In over 400&nbsp;patients treated with ACIPHEX Tablets (10 or 20&nbsp;mg/day) for up to one year, the incidence of ECL cell hyperplasia increased with time and dose, which is consistent with the pharmacological action of the proton-pump inhibitor. No patient developed the adenomatoid, dysplastic, or neoplastic changes of ECL cells in the gastric mucosa. No patient developed the carcinoid tumors observed in rats.</p>    <p> <span class="Underline">Endocrine Effects</span> </p>    <p>Studies in humans for up to one year have not revealed clinically significant effects on the endocrine system. In healthy male volunteers treated with ACIPHEX for 13&nbsp;days, no clinically relevant changes have been detected in the following endocrine parameters examined: 17&nbsp;β-estradiol, thyroid stimulating hormone, tri-iodothyronine, thyroxine, thyroxine-binding protein, parathyroid hormone, insulin, glucagon, renin, aldosterone, follicle-stimulating hormone, luteotrophic hormone, prolactin, somatotrophic hormone, dehydroepiandrosterone, cortisol-binding globulin, and urinary 6β-hydroxycortisol, serum testosterone and circadian cortisol profile.</p>    <p> <span class="Underline">Other Effects</span> </p>    <p>In humans treated with ACIPHEX for up to one year, no systemic effects have been observed on the central nervous, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems. No data are available on long-term treatment with ACIPHEX and ocular effects.</p>    <p> <span class="Underline">Microbiology</span> </p>    <p>The following <span class="Italics">in&nbsp;vitro</span> data are available but the clinical significance is unknown.</p>    <p>Rabeprazole sodium, amoxicillin, and clarithromycin as a three drug regimen has been shown to be active against most strains of <span class="Italics">Helicobacter pylori in&nbsp;vitro</span> and in clinical infections as described in the <span class="Italics">Clinical Studies</span> (<a href="#LINK_ce40b6d2-61a8-472c-b261-00151581773e">14</a>) and <span class="Italics">Indications and Usage</span> (<a href="#LINK_2f28a750-ab50-4569-89f2-744ba291d7d8">1</a>) sections.</p>    <p> <span class="Underline">Helicobacter pylori</span> </p>    <p>Susceptibility testing of <span class="Italics">H. pylori</span> isolates was performed for amoxicillin and clarithromycin using agar dilution methodology,<span class="Sup">1</span> and minimum inhibitory concentrations (MICs) were determined. </p>    <p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.</p>    <p> <span class="Underline">Incidence of Antibiotic-Resistant Organisms Among Clinical Isolates</span> </p>    <p> <span class="Bold"><span class="Italics">Pretreatment Resistance:</span></span> Clarithromycin pretreatment resistance rate (MIC ≥1&nbsp;μg/mL) to <span class="Italics">H.&nbsp;pylori</span> was 9% (51/ 560) at baseline in all treatment groups combined. A total of &gt;99% (558/560) of patients had <span class="Italics">H.&nbsp;pylori</span> isolates, which were considered to be susceptible (MIC ≤0.25&nbsp;μg/mL) to amoxicillin at baseline. Two patients had baseline <span class="Italics">H.&nbsp;pylori</span> isolates with an amoxicillin MIC of 0.5&nbsp;μg/mL.</p>    <p>For susceptibility testing information about <span class="Italics">Helicobacter pylori</span>, <span class="Italics">see Microbiology section in prescribing information for clarithromycin and amoxicillin</span>. </p>    <div class="scrollingtable">    <table>      <caption>       <span> TABLE 6 CLARITHROMYCIN SUSCEPTIBILITY TEST RESULTS AND CLINICAL/BACTERIOLOGIC OUTCOMES<span class="Sup">a</span>FOR A THREE DRUG REGIMEN (RABEPRAZOLE 20&nbsp;MG TWICE DAILY, AMOXICILLIN 1000&nbsp;MG TWICE DAILY, AND CLARITHROMYCIN 500&nbsp;MG TWICE DAILY FOR 7 OR 10&nbsp;DAYS) </span>      </caption>      <colgroup>      <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="8"><span class="Sup">a </span>Includes only patients with pretreatment and post-treatment clarithromycin susceptibility test results.<br /> <span class="Sup">b </span>Susceptible (S) MIC ≤0.25&nbsp;μg/mL, Intermediate (I) MIC&nbsp;= 0.5&nbsp;μg/mL, Resistant (R) MIC ≥1&nbsp;μg/mL </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">&nbsp; Days of RAC Therapy </td>       <td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">&nbsp; Clarithromycin Pretreatment Results </td>       <td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">&nbsp; Total Number </td>       <td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">&nbsp;<span class="Italics">H.&nbsp;pylori</span> Negative (Eradicated) </td>       <td class="Botrule Lrule Rrule Toprule" align="center" colspan="4">&nbsp;<span class="Italics">H.&nbsp;pylori</span> Positive <br />(Persistent)<br />Post-Treatment <br />Susceptibility Results </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; S<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; I<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; R<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; No MIC </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 7 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Susceptible<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 129 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 103 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 2 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 1 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 23 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 7 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Intermediate<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 7 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Resistant<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 16 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 5 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 2 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 1 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 4 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 4 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 10 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Susceptible<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 133 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 111 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 3 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 1 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 2 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 16 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 10 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Intermediate<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 10 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Resistant<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 9 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 1 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 5 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 3 </td>       </tr>      </tbody>     </table>   </div>    <p>Patients with persistent <span class="Italics">H.&nbsp;pylori</span> infection following rabeprazole, amoxicillin, and clarithromycin therapy will likely have clarithromycin resistant clinical isolates. Therefore, clarithromycin susceptibility testing should be done when possible. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted.</p>    <p> <span class="Italics">Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes:</span> In the U.S. multicenter study, a total of &gt;99% (558/560) of patients had <span class="Italics">H.&nbsp;pylori</span> isolates which were considered to be susceptible (MIC ≤0.25&nbsp;μg/mL) to amoxicillin at baseline. The other 2&nbsp;patients had baseline <span class="Italics">H.&nbsp;pylori</span> isolates with an amoxicillin MIC of 0.5&nbsp;μg/mL, and both isolates were clarithromycin-resistant at baseline; in one case the <span class="Italics">H.&nbsp;pylori</span> was eradicated. In the 7- and 10-day treatment groups, 75% (107/145) and 79% (112/142), respectively, of the patients who had pretreatment amoxicillin susceptible MICs (≤0.25&nbsp;μg/mL) were eradicated of <span class="Italics">H.&nbsp;pylori</span>. No patients developed amoxicillin-resistant <span class="Italics">H.&nbsp;pylori</span> during therapy.</p>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="LINK_e77f084a-2b81-444f-976e-0158612719d6"></a>   <a name="section-11.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics</h2>    <p class="First">ACIPHEX Delayed-Release Tablets and Delayed-Release granules in the capsule formulation are enteric-coated to allow rabeprazole sodium, which is acid labile, to pass through the stomach relatively intact.</p>    <p>After oral administration of 20&nbsp;mg ACIPHEX tablet, peak plasma concentrations (C<span class="Sub">max</span>) of rabeprazole occur over a range of 2.0 to 5.0&nbsp;hours (T<span class="Sub">max</span>). The rabeprazole C<span class="Sub">max</span> and AUC are linear over an oral dose range of 10&nbsp;mg to 40&nbsp;mg. There is no appreciable accumulation when doses of 10&nbsp;mg to 40&nbsp;mg are administered every 24&nbsp;hours; the pharmacokinetics of rabeprazole is not altered by multiple dosing.</p>    <p> <span class="Underline">Absorption:</span> Absolute bioavailability for a 20&nbsp;mg oral tablet of rabeprazole (compared to intravenous administration) is approximately 52%. When ACIPHEX Tablets are administered with a high fat meal, T<span class="Sub">max</span> is variable, which concomitant food intake may delay the absorption up to 4&nbsp;hours or longer. However, the C<span class="Sub">max</span> and the extent of rabeprazole absorption (AUC) are not significantly altered. Thus ACIPHEX Tablets may be taken without regard to timing of meals.</p>    <p>After oral administration to healthy adults of 10&nbsp;mg ACIPHEX granules sprinkled on applesauce under fasting condition, median time (T<span class="Sub">max</span>) to peak plasma concentrations (C<span class="Sub">max</span>) of rabeprazole was 2.5&nbsp;hours and ranged 1.0 to 6.5&nbsp;hours. The plasma half-life of rabeprazole ranges from 1 to 2&nbsp;hours.</p>    <p>In healthy adults, a concomitant high fat meal delayed the absorption of rabeprazole from ACIPHEX granules sprinkled on one Tablespoon of applesauce resulting in the median T<span class="Sub">max</span> of 4.5&nbsp;hours and decreased the C<span class="Sub">max,</span> and AUC<span class="Sub">last</span> on average by 55% and 33%, respectively. ACIPHEX granules should be taken before a meal.</p>    <p>When 10&nbsp;mg ACIPHEX granules administered under fasting conditions to healthy adults on one Tablespoon (15 mL) of applesauce, one Tablespoon (15 mL) of yogurt, or when mixed with a small amount (5 mL) of liquid infant formula, the type of soft food did not significantly affect T<span class="Sub">max</span>, C<span class="Sub">max</span> and AUC of rabeprazole.</p>    <p> <span class="Underline">Distribution:</span> Rabeprazole is 96.3% bound to human plasma proteins.</p>    <p> <span class="Underline">Metabolism:</span> Rabeprazole is extensively metabolized. A significant portion of rabeprazole is metabolized via systemic nonenzymatic reduction to a thioether compound. Rabeprazole is also metabolized to sulphone and desmethyl compounds via cytochrome P450 in the liver. The thioether and sulphone are the primary metabolites measured in human plasma. These metabolites were not observed to have significant antisecretory activity. <span class="Italics">In&nbsp;vitro</span> studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) to a sulphone metabolite and cytochrome P450 2C19 (CYP2C19) to desmethyl rabeprazole. CYP2C19 exhibits a known genetic polymorphism due to its deficiency in some sub-populations (e.g. 3 to 5% of Caucasians and 17 to 20% of Asians). Rabeprazole metabolism is slow in these sub-populations, therefore, they are referred to as poor metabolizers of the drug.</p>    <p> <span class="Underline">Elimination:</span> Following a single 20&nbsp;mg oral dose of <span class="Sup">14</span>C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid, its glucuronide, and mercapturic acid metabolites. The remainder of the dose was recovered in the feces. Total recovery of radioactivity was 99.8%. No unchanged rabeprazole was recovered in the urine or feces.</p>    <p> <span class="Underline">Geriatric:</span> In 20&nbsp;healthy elderly subjects administered 20&nbsp;mg rabeprazole tablet once daily for seven days, AUC values approximately doubled and the C<span class="Sub">max</span> increased by 60% compared to values in a parallel younger control group. There was no evidence of drug accumulation after once daily administration [<span class="Italics">see Use in Specific Population (<a href="#LINK_93834c41-64e1-415d-98e6-0e74ff226bf1">8.5</a>)</span>].</p>    <p> <span class="Underline">Pediatric:</span> The pharmacokinetics of rabeprazole was studied in pediatric patients with GERD aged up to 16&nbsp;years in four separate clinical studies.</p>    <p> <span class="Italics">Patients 12 to 16&nbsp;Years of Age</span> </p>    <p>The pharmacokinetics of rabeprazole was studied in 12&nbsp;adolescent patients with GERD 12 to 16&nbsp;years of age, in a multicenter study. Patients received rabeprazole 20&nbsp;mg tablets once daily for five or seven days. An approximate 40% increase in exposure was noted following 5 to 7&nbsp;days of dosing compared with the exposure after 1&nbsp;day dosing. Pharmacokinetic parameters in adolescent patients with GERD 12 to 16&nbsp;years of age were within the range observed in healthy adult volunteers.</p>    <p> <span class="Italics">Patients 1 to 11&nbsp;Years of Age</span> </p>    <p>In patients with GERD 1 to 11&nbsp;years of age, following once daily administration of rabeprazole granules at doses from 0.14 to 1&nbsp;mg/kg, the median time to peak plasma concentration ranged 2-4&nbsp;hours and the half-life was about 2.5&nbsp;hour. No appreciable accumulation was noted following 5&nbsp;days of dosing compared to exposure after a single dose.</p>    <p>Based on population pharmacokinetic analysis, over the body weight range from 7 to 77.3&nbsp;kg, the apparent rabeprazole clearance increased from 8.0 to 13.5&nbsp;L/hr, an increase of 68.8%.</p>    <p>The mean estimated total exposure, i.e., AUC after a 10&nbsp;mg dose of ACIPHEX Sprinkle in patients with GERD 1 to 11&nbsp;years of age, is comparable to a 10&nbsp;mg dose of ACIPHEX Tablets in adolescents and adults.</p>    <p> <span class="Italics">Patients &lt;1&nbsp;Year Old</span> </p>    <p>See section <a href="#LINK_4c0f43a6-1f88-4f79-a7ab-df1a60ea179c">8.4</a> Pediatric Use.</p>    <p> <span class="Underline">Gender and Race:</span> In analyses adjusted for body mass and height, rabeprazole pharmacokinetics showed no clinically significant differences between male and female subjects. In studies that used different formulations of rabeprazole, AUC<span class="Sub">0-∞</span> values for healthy Japanese men were approximately 50-60% greater than values derived from pooled data from healthy men in the United States.</p>    <p> <span class="Underline">Renal Disease:</span> In 10&nbsp;patients with stable end-stage renal disease requiring maintenance hemodialysis (creatinine clearance ≤5&nbsp;mL/min/1.73&nbsp;m<span class="Sup">2</span>), no clinically significant differences were observed in the pharmacokinetics of rabeprazole after a single 20&nbsp;mg oral dose when compared to 10&nbsp;healthy volunteers [<span class="Italics">see Dosage and Administration (<a href="#LINK_c471f22e-27c7-4f37-affe-13e17f1918d7">2.7</a>)</span>].</p>    <p> <span class="Underline">Hepatic Disease:</span> In a single dose study of 10&nbsp;patients with chronic mild to moderate compensated cirrhosis of the liver who were administered a 20&nbsp;mg dose of rabeprazole, AUC<span class="Sub">0-24</span> was approximately doubled, the elimination half-life was 2- to 3-fold higher, and total body clearance was decreased to less than half compared to values in healthy men.</p>    <p>In a multiple dose study of 12&nbsp;patients with mild to moderate hepatic impairment administered 20&nbsp;mg rabeprazole once daily for eight days, AUC<span class="Sub">0-∞</span> and C<span class="Sub">max</span> values increased approximately 20% compared to values in healthy age- and gender-matched subjects. These increases were not statistically significant.</p>    <p>No information exists on rabeprazole disposition in patients with severe hepatic impairment. Please refer to the <span class="Italics">Dosage and Administration (<a href="#LINK_c471f22e-27c7-4f37-affe-13e17f1918d7">2.7</a>)</span> for information on dosage adjustment in patients with hepatic impairment.</p>    <p> <span class="Underline">Combined Administration with Antimicrobials:</span> Sixteen healthy volunteers genotyped as extensive metabolizers with respect to CYP2C19 were given 20&nbsp;mg rabeprazole sodium, 1000&nbsp;mg amoxicillin, 500&nbsp;mg clarithromycin, or all 3&nbsp;drugs in a four-way crossover study. Each of the four regimens was administered twice daily for 6&nbsp;days. The AUC and C<span class="Sub">max</span> for clarithromycin and amoxicillin were not different following combined administration compared to values following single administration. However, the rabeprazole AUC and C<span class="Sub">max</span> increased by 11% and 34%, respectively, following combined administration. The AUC and C<span class="Sub">max</span> for 14-hydroxyclarithromycin (active metabolite of clarithromycin) also increased by 42% and 46%, respectively. This increase in exposure to rabeprazole and 14-hydroxyclarithromycin is not expected to produce safety concerns</p>    <p> <span class="Underline">Concomitant Use with Clopidogrel:</span> Clopidogrel is metabolized to its active metabolite in part by CYP2C19. A study of healthy subjects, including CYP2C19 extensive and intermediate metabolizers receiving once daily administration of clopidogrel 75&nbsp;mg concomitantly with placebo or with ACIPHEX 20&nbsp;mg (n=36), for 7&nbsp;days was conducted. The mean AUC of the active metabolite of clopidogrel was reduced by approximately 12% (mean AUC ratio was 88%, with 90% CI of 81.7 to 95.5%) when ACIPHEX was coadministered compared to administration of clopidogrel with placebo.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="LINK_b54a8ddb-8dd9-47fa-ad07-17c0a179f74a"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="LINK_9f22718a-9334-4c3a-bc90-298ce3ecfd97"></a>   <a name="section-12.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <p class="First">In a 88/104-week carcinogenicity study in CD-1 mice, rabeprazole at oral doses up to 100&nbsp;mg/kg/day did not produce any increased tumor occurrence. The highest tested dose produced a systemic exposure to rabeprazole (AUC) of 1.40&nbsp;μg•hr/mL, which is 1.6&nbsp;times the human exposure (plasma AUC<span class="Sub">0-∞</span>&nbsp;= 0.88&nbsp;μg•hr/mL) at the recommended dose for GERD (20&nbsp;mg/day). In a 28-week carcinogenicity study in p53<span class="Sup">+/-</span> transgenic mice, rabeprazole at oral doses of 20, 60, and 200&nbsp;mg/kg/day did not cause an increase in the incidence rates of tumors but produced gastric mucosal hyperplasia at all doses. The systemic exposure to rabeprazole at 200&nbsp;mg/kg/day is about 17 to 24&nbsp;times the human exposure at the recommended dose for GERD. In a 104-week carcinogenicity study in Sprague-Dawley rats, males were treated with oral doses of 5, 15, 30, and 60&nbsp;mg/kg/day and females with 5, 15, 30, 60, and 120&nbsp;mg/kg/day. Rabeprazole produced gastric enterochromaffin-like (ECL) cell hyperplasia in male and female rats and ECL cell carcinoid tumors in female rats at all doses including the lowest tested dose. The lowest dose (5&nbsp;mg/kg/day) produced a systemic exposure to rabeprazole (AUC) of about 0.1&nbsp;μg•hr/mL, which is about 0.1&nbsp;times the human exposure at the recommended dose for GERD. In male rats, no treatment related tumors were observed at doses up to 60&nbsp;mg/kg/day producing a rabeprazole plasma exposure (AUC) of about 0.2&nbsp;μg•hr/mL (0.2&nbsp;times the human exposure at the recommended dose for GERD).</p>    <p>Rabeprazole was positive in the Ames test, the Chinese hamster ovary cell (CHO/HGPRT) forward gene mutation test, and the mouse lymphoma cell (L5178Y/TK+/-) forward gene mutation test. Its demethylated-metabolite was also positive in the Ames test. Rabeprazole was negative in the <span class="Italics">in&nbsp;vitro</span> Chinese hamster lung cell chromosome aberration test, the <span class="Italics">in&nbsp;vivo</span> mouse micronucleus test, and the <span class="Italics">in&nbsp;vivo</span> and <span class="Italics">ex&nbsp;vivo</span> rat hepatocyte unscheduled DNA synthesis (UDS) tests.</p>    <p>Rabeprazole at intravenous doses up to 30&nbsp;mg/kg/day (plasma AUC of 8.8&nbsp;μg•hr/mL, about 10&nbsp;times the human exposure at the recommended dose for GERD) was found to have no effect on fertility and reproductive performance of male and female rats.</p>   </div>   <div class="Section" data-sectioncode="34091-9">    <a name="LINK_80f73198-a656-4944-a15c-f528a9e36eb8"></a>   <a name="section-12.2"></a>    <p></p>    <h2>13.2 Animal Toxicology and/or Pharmacology</h2>    <p class="First">Studies in juvenile and young adult rats and dogs were performed. In juvenile animal studies rabeprazole sodium was administered orally to rats for up to 5 weeks and to dogs for up to 13 weeks, each commencing on Day 7 post-partum and followed by a 13-week recovery period. Rats were dosed at 5, 25, or 150 mg/kg/day and dogs were dosed at 3, 10, or 30 mg/kg/day. The data from these studies were comparable to those reported for young adult animals. Pharmacologically mediated changes, including increased serum gastrin levels and stomach changes, were observed at all dose levels in both rats and dogs. These observations were reversible over the 13-week recovery periods. Although body weights and/or crown-rump lengths were minimally decreased during dosing, no effects on the development parameters were noted in either juvenile rats or dogs.</p>    <p>When juvenile animals were treated for 28 days with a different PPI at doses equal to or greater than 34 times the daily oral human dose on a body surface area basis, overall growth was affected and treatment-related decreases in body weight (approximately 14%) and body weight gain, and decreases in femur weight and femur length were observed.&nbsp; </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="LINK_ce40b6d2-61a8-472c-b261-00151581773e"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="LINK_ef90b590-892b-40a1-a4ec-8f363c3ed59a"></a>   <a name="section-13.1"></a>    <p></p>    <h2>14.1 Healing of Erosive or Ulcerative GERD in Adults</h2>    <p class="First">In a U.S. multicenter, randomized, double-blind, placebo-controlled study, 103&nbsp;patients were treated for up to eight weeks with placebo, 10&nbsp;mg, 20&nbsp;mg or 40&nbsp;mg ACIPHEX QD. For this and all studies of GERD healing, only patients with GERD symptoms and at least grade&nbsp;2 esophagitis (modified Hetzel-Dent grading scale) were eligible for entry. Endoscopic healing was defined as grade&nbsp;0 or 1. Each rabeprazole dose was significantly superior to placebo in producing endoscopic healing after four and eight weeks of treatment. The percentage of patients demonstrating endoscopic healing was as follows:</p>    <div class="scrollingtable">    <table>      <caption>       <span> TABLE 7 HEALING OF EROSIVE OR ULCERATIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) PERCENTAGE OF PATIENTS HEALED </span>      </caption>      <colgroup>      <col width="14%" />       <col width="22%" />       <col width="22%" />       <col width="22%" />       <col width="20%" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="5">&nbsp; *(p&lt;0.001 versus placebo) </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp; Week </td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp; 10&nbsp;mg<br />ACIPHEX QD<br />N=27 </td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp; 20&nbsp;mg<br />ACIPHEX QD<br />N=25 </td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp; 40&nbsp;mg<br />ACIPHEX QD<br />N=26 </td>       <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp; Placebo<br />N=25 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 4 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 63%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 56%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 54%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 0% </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 8 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 93%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 84%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 85%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 12% </td>       </tr>      </tbody>     </table>   </div>    <p>In addition, there was a statistically significant difference in favor of the ACIPHEX 10&nbsp;mg, 20&nbsp;mg, and 40&nbsp;mg doses compared to placebo at Weeks&nbsp;4 and 8 regarding complete resolution of GERD heartburn frequency (p≤0.026). All ACIPHEX groups reported significantly greater rates of complete resolution of GERD daytime heartburn severity compared to placebo at Weeks&nbsp;4 and 8 (p≤0.036). Mean reductions from baseline in daily antacid dose were statistically significant for all ACIPHEX groups when compared to placebo at both Weeks&nbsp;4 and 8 (p≤0.007).</p>    <p>In a North American multicenter, randomized, double-blind, active-controlled study of 336&nbsp;patients, ACIPHEX was statistically superior to ranitidine with respect to the percentage of patients healed at endoscopy after four and eight weeks of treatment (see table below): </p>    <div class="scrollingtable">    <table>      <caption>       <span> TABLE 8 HEALING OF EROSIVE OR ULCERATIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) PERCENTAGE OF PATIENTS HEALED </span>      </caption>      <colgroup>      <col width="20%" />       <col width="40%" />       <col width="40%" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="3">&nbsp; *(p&lt;0.001 versus ranitidine) </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">&nbsp; Week </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">&nbsp; ACIPHEX 20&nbsp;mg QD<br />N=167 </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">&nbsp; Ranitidine 150&nbsp;mg QID<br />N=169 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 4 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 59%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 36% </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 8 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 87%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 66% </td>       </tr>      </tbody>     </table>   </div>    <p>ACIPHEX 20&nbsp;mg once daily was significantly more effective than ranitidine 150&nbsp;mg QID in the percentage of patients with complete resolution of heartburn at Weeks&nbsp;4 and 8 (p&lt;0.001). ACIPHEX 20&nbsp;mg once daily was also more effective in complete resolution of daytime heartburn (p≤0.025), and nighttime heartburn (p≤0.012) at both Weeks&nbsp;4 and 8, with significant differences by the end of the first week of the study.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_c8d21df2-b50e-4cd1-8195-5f54b03662f3"></a>   <a name="section-13.2"></a>    <p></p>    <h2>14.2 Long-term Maintenance of Healing of Erosive or Ulcerative GERD in Adults</h2>    <p class="First">The long-term maintenance of healing in patients with erosive or ulcerative GERD previously healed with gastric antisecretory therapy was assessed in two U.S. multicenter, randomized, double-blind, placebo-controlled studies of identical design of 52&nbsp;weeks duration. The two studies randomized 209 and 285&nbsp;patients, respectively, to receive either 10&nbsp;mg or 20&nbsp;mg of ACIPHEX QD or placebo. As demonstrated in the tables below, ACIPHEX was significantly superior to placebo in both studies with respect to the maintenance of healing of GERD and the proportions of patients remaining free of heartburn symptoms at 52&nbsp;weeks:</p>    <div class="scrollingtable">    <table>      <caption>       <span> TABLE 9 PERCENT OF PATIENTS IN ENDOSCOPIC REMISSION </span>      </caption>      <colgroup>      <col width="25%" />       <col width="25%" />       <col width="25%" />       <col width="25%" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="4">*(p&lt;0.001 versus placebo) </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" valign="top">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp; ACIPHEX 10&nbsp;mg </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp; ACIPHEX 20&nbsp;mg </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp; Placebo </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">Study&nbsp;1 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; N=66 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; N=67 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; N=70 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;4 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 83%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 96%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 44% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;13 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 79%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 93%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 39% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;26 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 77%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 93%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 31% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;39 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 76%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 91%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 30% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;52 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 73%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 90%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 29% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">Study&nbsp;2 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; N=93 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; N=93 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; N=99 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;4 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 89%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 94%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 40% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;13 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 86%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 91%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 33% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;26 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 85%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 89%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 30% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;39 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 84%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 88%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 29% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;52 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 77%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 86%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 29% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">COMBINED <br />STUDIES </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; N=159 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; N=160 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; N=169 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;4 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 87%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 94%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 42% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;13 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 83%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 92%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 36% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;26 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 82%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 91%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 31% </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;39 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 81%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 89%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 30% </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Week&nbsp;52 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 75%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 87%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 29% </td>       </tr>      </tbody>     </table>   </div>    <div class="scrollingtable">    <table>      <caption>       <span> TABLE 10 PERCENT OF PATIENTS WITHOUT RELAPSE IN HEARTBURN FREQUENCY AND DAYTIME AND NIGHTTIME HEARTBURN SEVERITY AT WEEK&nbsp;52 </span>      </caption>      <colgroup>      <col width="31%" />       <col width="23%" />       <col width="23%" />       <col width="23%" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="4">* p≤0.001 versus placebo<br /> <span class="Sup">†</span> 0.001&lt;p&lt;0.05 versus placebo </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" valign="bottom">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">&nbsp; ACIPHEX<br />10&nbsp;mg </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">&nbsp; ACIPHEX<br />20&nbsp;mg </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">&nbsp; Placebo </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; Heartburn <br />&nbsp; Frequency </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;</td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;</td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Study&nbsp;1 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 46/55 (84%)* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 48/52 (92%)* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 17/45 (38%) </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Study&nbsp;2 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 50/72 (69%)* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 57/72 (79%)* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 22/79 (28%) </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; Daytime Heartburn <br />&nbsp; Severity </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;</td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;</td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Study&nbsp;1 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 61/64 (95%)* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 60/62 (97%)* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 42/61 (69%) </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Study&nbsp;2 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 73/84 (87%)<span class="Sup">†</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 82/87 (94%)* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 67/90 (74%) </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; Nighttime Heartburn <br />&nbsp; Severity </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;</td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;</td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Study&nbsp;1 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 57/61 (93%)* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 60/61 (98%)* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 37/56 (66%) </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" valign="top">&nbsp; &nbsp;&nbsp;&nbsp;Study&nbsp;2 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 67/80 (84%) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 79/87 (91%)<span class="Sup">†</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 64/87 (74%) </td>       </tr>      </tbody>     </table>   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_09021349-acbf-4b90-9654-c1b54d8f8d2d"></a>   <a name="section-13.3"></a>    <p></p>    <h2>14.3 Treatment of Symptomatic GERD in Adults</h2>    <p class="First">Two U.S. multicenter, double-blind, placebo-controlled studies were conducted in 316 adult patients with daytime and nighttime heartburn. Patients reported 5 or more periods of moderate to very severe heartburn during the placebo treatment phase the week prior to randomization. Patients were confirmed by endoscopy to have no esophageal erosions.</p>    <p>The percentage of heartburn free daytime and/or nighttime periods was greater with ACIPHEX 20&nbsp;mg compared to placebo over the 4&nbsp;weeks of study in Study RAB-USA-2 (47% vs. 23%) and Study RAB-USA-3 (52% vs. 28%). The mean decreases from baseline in average daytime and nighttime heartburn scores were significantly greater for ACIPHEX 20&nbsp;mg as compared to placebo at week&nbsp;4. Graphical displays depicting the daily mean daytime and nighttime scores are provided in Figures&nbsp;2 to 5.</p>    <p>FIGURE 2: MEAN DAYTIME HEARTBURN SCORES RAB-USA-2<br /> <img src="image.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&name=aciphex%2D2%2Ejpg" alt="FIGURE 2: MEAN DAYTIME HEARTBURN SCORES RAB-USA-2" /></p>    <p>FIGURE 3: MEAN NIGHTTIME HEARTBURN SCORES RAB-USA-2<br /> <img src="image.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&name=aciphex%2D3%2Ejpg" alt="FIGURE 3: MEAN NIGHTTIME HEARTBURN SCORES RAB-USA-2" /></p>    <p>FIGURE 4: MEAN DAYTIME HEARTBURN SCORES RAB-USA-3<br /> <img src="image.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&name=aciphex%2D4%2Ejpg" alt="FIGURE 4: MEAN DAYTIME HEARTBURN SCORES RAB-USA-3" /></p>    <p>FIGURE 5: MEAN NIGHTTIME HEARTBURN SCORES RAB-USA-3<br /> <img src="image.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&name=aciphex%2D5%2Ejpg" alt="FIGURE 5: MEAN NIGHTTIME HEARTBURN SCORES RAB-USA-3" /></p>    <p>In addition, the combined analysis of these two studies showed ACIPHEX 20&nbsp;mg significantly improved other GERD-associated symptoms (regurgitation, belching, and early satiety) by week&nbsp;4 compared with placebo (all p values &lt;&nbsp;0.005).</p>    <p>ACIPHEX 20&nbsp;mg also significantly reduced daily antacid consumption versus placebo over 4&nbsp;weeks (p&lt;0.001).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_95c8c64d-f59d-48b9-8d4c-e550a6c08685"></a>   <a name="section-13.4"></a>    <p></p>    <h2>14.4 Healing of Duodenal Ulcers in Adults</h2>    <p class="First">In a U.S. randomized, double-blind, multicenter study assessing the effectiveness of 20&nbsp;mg and 40&nbsp;mg of ACIPHEX QD versus placebo for healing endoscopically defined duodenal ulcers, 100&nbsp;patients were treated for up to four weeks. ACIPHEX was significantly superior to placebo in producing healing of duodenal ulcers. The percentages of patients with endoscopic healing are presented below:</p>    <div class="scrollingtable">    <table>      <caption>       <span> TABLE 11 HEALING OF DUODENAL ULCERS PERCENTAGE OF PATIENTS HEALED </span>      </caption>      <colgroup>      <col width="16%" />       <col width="30%" />       <col width="30%" />       <col width="24%" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="4">&nbsp; * p≤0.001 versus placebo </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center">&nbsp; Week </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp; ACIPHEX 20&nbsp;mg <br />QD<br />N=34 </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp; ACIPHEX 40&nbsp;mg <br />QD<br />N=33 </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp; Placebo<br />N=33 </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 2 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 44% </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 42% </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 21% </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 4 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 79%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 91%* </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 39% </td>       </tr>      </tbody>     </table>   </div>    <p>At Weeks&nbsp;2 and 4, significantly more patients in the ACIPHEX 20 and 40&nbsp;mg groups reported complete resolution of ulcer pain frequency (p≤0.018), daytime pain severity (p≤0.023), and nighttime pain severity (p≤0.035) compared with placebo patients. The only exception was the ACIPHEX 40&nbsp;mg group versus placebo at Week&nbsp;2 for duodenal ulcer pain frequency (p=0.094). Significant differences in resolution of daytime and nighttime pain were noted in both ACIPHEX groups relative to placebo by the end of the first week of the study. Significant reductions in daily antacid use were also noted in both ACIPHEX groups compared to placebo at Weeks&nbsp;2 and 4 (p&lt;0.001).</p>    <p>An international randomized, double-blind, active-controlled trial was conducted in 205&nbsp;patients comparing 20&nbsp;mg ACIPHEX QD with 20&nbsp;mg omeprazole QD. The study was designed to provide at least 80% power to exclude a difference of at least 10% between ACIPHEX and omeprazole, assuming four-week healing response rates of 93% for both groups. In patients with endoscopically defined duodenal ulcers treated for up to four weeks, ACIPHEX was comparable to omeprazole in producing healing of duodenal ulcers. The percentages of patients with endoscopic healing at two and four weeks are presented below: </p>    <div class="scrollingtable">    <table>      <caption>       <span> TABLE 12 HEALING OF DUODENAL ULCERS PERCENTAGE OF PATIENTS HEALED </span>      </caption>      <colgroup>      <col width="16%" />       <col width="25%" />       <col width="25%" />       <col width="34%" />      </colgroup>     <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center">Week </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ACIPHEX<br />20&nbsp;mg QD<br />N=102 </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Omeprazole<br />20&nbsp;mg QD<br />N=103 </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">95% Confidence <br />Interval for<br /> the Treatment <br />Difference <br />(ACIPHEX&nbsp;- <br />Omeprazole) </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 2 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 69% </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 61% </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; (-6%, 22%) </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 4 </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 98% </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 93% </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; (-3%, 15%) </td>       </tr>      </tbody>     </table>   </div>    <p>ACIPHEX and omeprazole were comparable in providing complete resolution of symptoms.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_2ebde5d5-074e-4dd9-b7a5-5ae818765dd9"></a>   <a name="section-13.5"></a>    <p></p>    <h2>14.5 <span class="Italics">Helicobacter pylori</span> Eradication in Patients with Peptic Ulcer Disease or Symptomatic Non-Ulcer Disease in Adults</h2>    <p class="First">The U.S. multicenter study was a double-blind, parallel-group comparison of rabeprazole, amoxicillin, and clarithromycin for 3, 7, or 10&nbsp;days vs. omeprazole, amoxicillin, and clarithromycin for 10&nbsp;days. Therapy consisted of rabeprazole 20&nbsp;mg twice daily, amoxicillin 1000&nbsp;mg twice daily, and clarithromycin 500&nbsp;mg twice daily (RAC) or omeprazole 20&nbsp;mg twice daily, amoxicillin 1000&nbsp;mg twice daily, and clarithromycin 500&nbsp;mg twice daily (OAC). Patients with <span class="Italics">H.&nbsp;pylori</span> infection were stratified in a 1:1 ratio for those with peptic ulcer disease (active or a history of ulcer in the past five years) [PUD] and those who were symptomatic but without peptic ulcer disease [NPUD], as determined by upper gastrointestinal endoscopy. The overall <span class="Italics">H.&nbsp;pylori</span> eradication rates, defined as negative <span class="Sup">13</span>C-UBT for <span class="Italics">H.&nbsp;pylori</span> ≥6&nbsp;weeks from the end of the treatment are shown in the following table. The eradication rates in the 7-day and 10-day RAC regimens were found to be similar to 10-day OAC regimen using either the Intent-to-Treat (ITT) or Per-Protocol (PP) populations. Eradication rates in the RAC 3-day regimen were inferior to the other regimens.</p>    <div class="scrollingtable">    <table width="700px">      <caption>       <span>TABLE 13 HELICOBACTER PYLORI ERADICATION AT ≥ 6 WEEKS AFTER THE END OF TREATMENT </span>      </caption>      <colgroup>      <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="4"><span class="Sup">a</span>Patients were included in the analysis if they had <span class="Italics">H.&nbsp;pylori</span> infection documented at baseline, defined as a positive <span class="Sup">13</span>C-UBT plus rapid urease test or culture, and were not protocol violators. Patients who dropped out of the study due to an adverse event related to the study drug were included in the evaluable analysis as failures of therapy.<br /> <span class="Sup">b</span>Patients were included in the analysis if they had documented <span class="Italics">H.&nbsp;pylori</span> infection at baseline as defined above and took at least one dose of study medication. All dropouts were included as failures of therapy.<br />*The 95% confidence intervals for the difference in eradication rates for 7-day RAC minus 10-day RAC are (-&nbsp;9.3, 6.0) in the PP population and (-9.0, 7.5) in the ITT population. </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp;</td>       <td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">&nbsp; Treatment Group<br />Percent (%) of Patients Cured<br />(Number of Patients) </td>       <td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&nbsp; Difference<br />(RAC&nbsp;- OAC)<br />[95% Confidence Interval] </td>       </tr>       <tr>        <td class="Botrule Lrule" align="center" valign="top">&nbsp;</td>       <td class="Botrule" align="center" valign="top">&nbsp;<span class="Bold">7-day RAC*</span></td>       <td class="Botrule" align="center" valign="top">&nbsp;<span class="Bold">10-day OAC</span></td>       <td class="Botrule Rrule" align="center" valign="top">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Per Protocol<span class="Sup">a</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 84.3%<br />(N=166) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 81.6%<br />(N=179) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 2.8<br />[-&nbsp;5.2, 10.7] </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Intent-to-Treat<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 77.3%<br />(N=194) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 73.3%<br />(N=206) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 4.0<br />[-&nbsp;4.4, 12.5] </td>       </tr>       <tr>        <td class="Botrule Lrule" align="center" valign="top">&nbsp;</td>       <td class="Botrule" align="center" valign="top">&nbsp;<span class="Bold">10-day RAC*</span></td>       <td class="Botrule" align="center" valign="top">&nbsp;<span class="Bold">10-day OAC</span></td>       <td class="Botrule Rrule" align="center" valign="top">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Per Protocol<span class="Sup">a</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 86.0%<br />(N=171) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 81.6%<br />(N=179) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 4.4<br />[-&nbsp;3.3, 12.1] </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Intent-to-Treat<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 78.1%<br />(N=196) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 73.3%<br />(N=206) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 4.8<br />[-&nbsp;3.6, 13.2] </td>       </tr>       <tr>        <td class="Botrule Lrule" align="center" valign="top">&nbsp;</td>       <td class="Botrule" align="center" valign="top">&nbsp;<span class="Bold">3-day RAC</span></td>       <td class="Botrule" align="center" valign="top">&nbsp;<span class="Bold">10-day OAC</span></td>       <td class="Botrule Rrule" align="center" valign="top">&nbsp;</td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Per Protocol<span class="Sup">a</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 29.9%<br />(N=167) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 81.6%<br />(N=179) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; -&nbsp;51.6<br />[-&nbsp;60.6, -&nbsp;42.6] </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; Intent-to-Treat<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 27.3%<br />(N=187) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 73.3%<br />(N=206) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; -&nbsp;46.0<br />[-&nbsp;54.8, -&nbsp;37.2] </td>       </tr>      </tbody>     </table>   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_f97d6e11-7c70-41ea-a9c2-02d9c75a71d3"></a>   <a name="section-13.6"></a>    <p></p>    <h2> 14.6 Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults </h2>    <p class="First">Twelve patients with idiopathic gastric hypersecretion or Zollinger-Ellison syndrome have been treated successfully with ACIPHEX at doses from 20 to 120&nbsp;mg for up to 12&nbsp;months. ACIPHEX produced satisfactory inhibition of gastric acid secretion in all patients and complete resolution of signs and symptoms of acid-peptic disease where present. ACIPHEX also prevented recurrence of gastric hypersecretion and manifestations of acid-peptic disease in all patients. The high doses of ACIPHEX used to treat this small cohort of patients with gastric hypersecretion were well tolerated.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="LINK_b43f20dc-7f62-4fbd-a34f-f0d238c27276"></a>   <a name="section-13.7"></a>    <p></p>    <h2>14.7 Pediatric GERD</h2>    <p class="First"> <span class="Italics">Symptomatic GERD in Adolescents 12 to 16&nbsp;Years of Age</span> </p>    <p>In a multicenter, randomized, open-label, parallel-group study, 111 adolescent patients 12 to 16&nbsp;years of age with a clinical diagnosis of symptomatic GERD or suspected or endoscopically proven GERD were randomized and treated with either ACIPHEX 10&nbsp;mg or ACIPHEX 20&nbsp;mg once daily for up to 8&nbsp;weeks for the evaluation of safety and efficacy.</p>    <p> <span class="Italics">GERD in Pediatric Patients 1 to 11&nbsp;Years of Age</span> </p>    <p>The use of ACIPHEX Sprinkle in pediatric patients 1 to 11&nbsp;years of age is supported by a two-part, multicenter, randomized, double-blind, parallel 2&nbsp;dose arms clinical trial which was conducted in 127 pediatric patients with endoscopic and histologic evidence of GERD prior to study treatment.</p>    <p>Part&nbsp;1 was 12&nbsp;weeks in duration. Patients were randomized to one of two rabeprazole dose levels based on body weight. Patients weighing 6.0 to 14.9&nbsp;kg received either 5 or 10&nbsp;mg rabeprazole, and those with body weight ≥15&nbsp;kg received either 10 or 20&nbsp;mg of rabeprazole. Part&nbsp;2 was a 24-week double-blinded extension of Part&nbsp;1 (on same dose assigned in Part&nbsp;1). Endoscopic evaluations were performed at 12&nbsp;weeks (Part&nbsp;1) and 36&nbsp;weeks (Part&nbsp;2) to assess esophageal healing. No prespecified formal hypothesis testing was conducted.</p>    <p>For Part&nbsp;1, rates of endoscopic healing were calculated and are shown in Table&nbsp;14.</p>    <div class="scrollingtable">    <table>      <caption>       <span> TABLE 14 SHORT-TERM (12-WEEK) HEALING RATES IN 1- to 11-&nbsp;YEAR-OLD CHILDREN (PART&nbsp;1) </span>      </caption>      <colgroup>      <col width="1px" />       <col width="1px" />       <col width="1px" />       <col width="1px" />      </colgroup>     <tfoot>       <tr class="First Last">        <td colspan="4"><span class="Sup">a</span>Hetzel-Dent score ≥2<br /> <span class="Sup">b</span>Hetzel-Dent score = 1 </td>       </tr>      </tfoot>      <tbody class="Headless">       <tr class="First">        <td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">&nbsp;<span class="Bold">Endoscopic <br />Classification <br />of GERD</span> <br /> <span class="Bold">At Baseline</span></td>       <td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">&nbsp;<span class="Bold">Healing Rate</span> <br /> <span class="Bold">at 12&nbsp;weeks</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top">&nbsp;<span class="Bold">Body Weight &lt;15&nbsp;kg</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;<span class="Bold">Body Weight ≥15&nbsp;kg</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;<span class="Bold">&nbsp;</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;<span class="Bold">5&nbsp;mg dose</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;<span class="Bold">10&nbsp;mg dose</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp;<span class="Bold">10&nbsp;mg dose</span></td>       </tr>       <tr>        <td class="Botrule Lrule Rrule" valign="top">&nbsp; Erosive<span class="Sup">a</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 88%<br />(7/8) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 83%<br />(5/6) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 71%<br />(12/17) </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule" valign="top">&nbsp; Non-erosive<span class="Sup">b</span></td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 78%<br />(7/9) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 100%<br />(10/10) </td>       <td class="Botrule Lrule Rrule" align="center" valign="top">&nbsp; 81%<br />(17/21) </td>       </tr>      </tbody>     </table>   </div>    <p>Of the 87&nbsp;patients with healing in Part&nbsp;1, 64&nbsp;patients were enrolled into Part&nbsp;2. The absence of a placebo group does not allow assessment of sustained efficacy through 36&nbsp;weeks. Of the 52&nbsp;patients with available data, healing was observed in 47 (90%) patients at 36&nbsp;weeks.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">15 REFERENCES</a> <div class="Section toggle-content closed" data-sectioncode="34093-5">   <a name="LINK_636a3cb8-28ec-4d58-b40d-ed7eaf007f4c"></a>  <a name="section-14"></a>   <p></p>    <ol class="Arabic">    <li>National Committee for Clinical Laboratory Standards. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically</span>-Fifth Edition. Approved Standard NCCLS Document M7-A5, Vol. 20, No. 2, NCCLS, Wayne, PA, January 2000.</li>   </ol>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="LINK_38cfdb3b-152b-43d1-8801-a3ee5056569a"></a>  <a name="section-15"></a>   <p></p>    <p class="First">ACIPHEX 20 mg is supplied as delayed-release light yellow enteric-coated tablets. The name and strength, in mg, (ACIPHEX 20) is imprinted on one side.</p>   <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bottles of 30 (NDC 62856-243-30)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bottles of 90 (NDC 62856-243-90)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unit Dose Blisters Package of 100 (10 x 10) (NDC 62856-243-41)</p>   <p>Store at 25&deg;C (77&deg;F); excursions permitted to 15-30&deg;C (59-86&deg;F) [<span class="Italics">see</span> USP Controlled Room Temperature]. Protect from moisture.</p>   <p>ACIPHEX Sprinkle (5 mg) is supplied as transparent blue and opaque white capsules containing enteric coated granules. Identification and strength (ACX 5mg) are imprinted on the body of the capsule. An arrow (↑) imprint on the capsule cap indicates direction for opening a capsule.</p>   <p>Bottles of 30 (NDC 13551-205-01)</p>   <p>ACIPHEX Sprinkle (10 mg) is supplied as transparent yellow and opaque white capsules containing enteric coated granules. Identification and strength (ACX 10mg) are imprinted on the body of the capsule. An arrow (↑) imprint on the capsule cap indicates direction for opening a capsule.</p>   <p>Bottles of 30 (NDC 13551-210-01)</p>   <p>Store at 25&deg;C (77&deg;F); excursions permitted to 15-30&deg;C (59-86&deg;F) [<span class="Italics">see</span> USP Controlled Room Temperature]. Protect from moisture.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="LINK_7ee8f2ee-49f4-4fc9-915b-43a125354648"></a>  <a name="section-16"></a>   <p></p>    <p class="First">See FDA-approved patient labeling (<a href="#LINK_df25b6bc-e484-4b4b-bec4-8021d1f14003">Medication Guide</a>)</p>   <p> <span class="Bold">How to Take ACIPHEX</span> </p>   <p>Patients should be cautioned that ACIPHEX Delayed-Release Tablets should be swallowed whole. The tablets should not be chewed, crushed, or split. ACIPHEX can be taken with or without food.</p>   <p>ACIPHEX Sprinkle Delayed-Release Capsules should be opened and the granule contents sprinkled on a small amount of soft food (e.g., apple sauce, fruit, or vegetable based baby food, or yogurt) or empty contents into a small amount of liquid (e.g., infant formula, apple juice, or pediatric electrolyte solution). Food or liquid should be at or below room temperature. The whole dose should be taken within 15&nbsp;minutes of being sprinkled. The granules should not be chewed or crushed. The dose should be taken 30&nbsp;minutes before a meal. Do not store mixture for future use.</p>   <p>Advise patient to immediately report and seek care for diarrhea that does not improve. This may be a sign of <span class="Italics">Clostridium difficile</span> associated diarrhea [<span class="Italics">see Warnings and Precautions (<a href="#LINK_269ec7f5-ce7a-4374-ab63-8df125265326">5.5</a>)</span>].</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">MEDICATION GUIDE</a> <div class="Section toggle-content closed" data-sectioncode="42231-1">   <a name="LINK_df25b6bc-e484-4b4b-bec4-8021d1f14003"></a>  <a name="section-17"></a>   <p></p>   <h1></h1>   <p class="First"> <span class="Bold">MEDICATION GUIDE</span> </p>   <p> <span class="Bold">ACIPHEX<span class="Sup">&reg;</span> (a-se-feks)</span> <br /> <span class="Bold">(rabeprazole sodium)</span> <br /> <span class="Bold">Delayed-Release Tablets</span> </p>   <p> <span class="Bold">ACIPHEX<span class="Sup">(R)</span> Sprinkle™ (a-se-feks spr-en-kle)</span> <br /> <span class="Bold">(rabeprazole sodium)</span> <br /> <span class="Bold">Delayed-Release Capsules</span> </p>   <p>Read the Medication Guide that comes with ACIPHEX before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment.</p>   <p> <span class="Bold">What is the most important information I should know about ACIPHEX?</span> </p>   <p> <span class="Bold">ACIPHEX may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor.</span> </p>   <p> <span class="Bold">ACIPHEX can cause serious side effects, including:</span> </p>   <ul class="Disk">    <li> <span class="Bold">Diarrhea.</span> ACIPHEX may increase your risk of getting severe diarrhea. This diarrhea may be caused by an infection (<span class="Italics">Clostridium difficile</span>) in your intestines.<br /> <br />Call your doctor right away if you have watery stool, stomach pain, and fever that does not go away.<br />&nbsp; </li>    <li> <span class="Bold">Bone fractures.</span> People who take multiple daily doses of Proton Pump Inhibitor (PPI) medicines for a long period of time (1 year or longer) may have an increased risk of fractures of the hip, wrist, or spine. You should take ACIPHEX exactly as prescribed, at the lowest dose possible for your treatment and for the shortest time needed. Talk to your doctor about your risk of bone fracture if you take ACIPHEX.<br /> <br />ACIPHEX can have other serious side effects. See <span class="Bold">&quot;What are the possible side effects of ACIPHEX?&quot;</span> </li>   </ul>   <p> <span class="Bold">What is ACIPHEX?</span> </p>   <p>ACIPHEX is a prescription medicine called a Proton Pump Inhibitor (PPI). ACIPHEX reduces the amount of acid in your stomach.</p>   <p>ACIPHEX is used in adults:</p>   <ul class="Disk">    <li>for up to 8&nbsp;weeks to heal acid-related damage to the lining of the esophagus (called erosive esophagitis or EE) and to relieve symptoms, such as heartburn pain. If needed, your doctor may decide to prescribe another 8&nbsp;weeks of ACIPHEX. </li>    <li>to maintain the healing of the esophagus and relief of symptoms related to EE. It is not known if ACIPHEX is safe and effective if used longer than 12&nbsp;months (1&nbsp;year). </li>    <li>for 4&nbsp;weeks to treat daytime and nighttime heartburn and other symptoms that happen with Gastroesophageal Reflux Disease (GERD).<br /> <br />GERD happens when acid in your stomach backs up into the tube (esophagus) that connects your mouth to your stomach. This may cause a burning feeling in your chest or throat, sour taste, or burping.<br />&nbsp; </li>    <li>for up to 4&nbsp;weeks for the healing and relief of duodenal ulcers. The duodenal area is the area where food passes when it leaves the stomach. </li>    <li>For 7&nbsp;days with certain antibiotic medicines to treat an infection caused by bacteria called <span class="Italics">H.&nbsp;pylori</span>. Sometimes <span class="Italics">H.&nbsp;pylori</span> bacteria can cause duodenal ulcers. The infection needs to be treated to prevent the ulcers from coming back. </li>    <li>for the long-term treatment of conditions where your stomach makes too much acid. This includes a rare condition called Zollinger-Ellison syndrome.</li>   </ul>   <p>ACIPHEX is used in adolescents 12&nbsp;years of age and older to treat symptoms of Gastroesophageal Reflux Disease (GERD) for up to 8 weeks.</p>   <p>ACIPHEX is used in children 1 to 11&nbsp;years of age to treat GERD for up to 12 weeks.</p>   <p>ACIPHEX is not effective in treating symptoms of GERD in children 1 month to 11 months of age.</p>   <p>ACIPHEX should not be used to treat GERD in babies younger than 1 month of age.</p>   <p> <span class="Bold">Who should not take ACIPHEX?</span> </p>   <p> <span class="Bold">Do not take ACIPHEX if you:</span> </p>   <ul class="Disk">    <li>are allergic to rabeprazole or any of the other ingredients in ACIPHEX. See the end of this Medication Guide for a complete list of ingredients in ACIPHEX. </li>    <li>are allergic to any other Proton Pump Inhibitor (PPI) medicine.</li>   </ul>   <p> <span class="Bold">What should I tell my doctor before taking ACIPHEX?</span> </p>   <p> <span class="Bold">Before you take ACIPHEX tell your doctor about all of your medical conditions, including if you:</span> </p>   <ul class="Disk">    <li>have been told that you have low magnesium levels in your blood. </li>    <li>have liver problems. </li>    <li>have any allergies. </li>    <li>have any other medical conditions. </li>    <li>are pregnant or planning to become pregnant. It is not known if ACIPHEX can harm your unborn baby. </li>    <li>are breastfeeding. It is not known if ACIPHEX passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take ACIPHEX.</li>   </ul>   <p> <span class="Bold">Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.</span> ACIPHEX may affect how other medicines work, and other medicines may affect how ACIPHEX works.</p>   <p>Especially tell your doctor if you take:</p>   <ul class="Disk">    <li>atazanavir (Reyataz) </li>    <li>cyclosporine (Sandimmune, Neoral) </li>    <li>digoxin (Lanoxin) </li>    <li>ketoconazole (Nizoral) </li>    <li>warfarin (Coumadin) </li>    <li>theophylline (THEO-24 Thelair) </li>    <li>diazepam (Valium) </li>    <li>phenytoin (Dilantin) </li>    <li>an antibiotic that contains amoxicillin or clarithromycin </li>    <li>a &quot;water pill&quot; (diuretic) </li>    <li>methotrexate</li>    <li>mycophenolate mofetil (Cellcept) </li>   </ul>   <p>Ask your doctor or pharmacist for a list of these medicines, if you are not sure.</p>   <p>Know the medicines that you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>   <p> <span class="Bold">How should I take ACIPHEX?</span> </p>   <ul class="Disk">    <li>Take ACIPHEX exactly as prescribed. Your doctor will prescribe the dose that is right for you and your medical condition. Do not change your dose or stop taking ACIPHEX unless you talk to your doctor. Take ACIPHEX for as long as it is prescribed even if you feel better. </li>    <li>ACIPHEX is usually taken one time each day. Your doctor will tell you the time of day to take ACIPHEX, based on your medical condition. </li>    <li> <span class="Bold">ACIPHEX Tablets</span> can be taken with or without food. Your doctor will tell you whether to take this medicine with or without food based on your medical condition. </li>    <li>Swallow each <span class="Bold">ACIPHEX Tablet</span> whole with water. <span class="Bold">Do not chew, crush, or split ACIPHEX Tablets.</span> Tell your doctor if you cannot swallow tablets whole. </li>    <li> <span class="Bold">Take a dose of ACIPHEX Sprinkle Delayed-Release Capsules</span> as follows:     <ul class="Circle">      <li>Take the dose 30&nbsp;minutes before a meal. </li>      <li>Open the capsule and sprinkle the contents onto a small amount of soft food such as apple sauce, fruit, or vegetable based baby food, or yogurt. You may also empty the capsule contents into a small amount of infant formula, apple juice, or a pediatric electrolyte solution such as Pedialyte<span class="Sup">&reg;</span>. The food or liquid that you use should be at or below room temperature. </li>      <li> <span class="Bold">Swallow the entire mixture. Do not chew or crush the granules.</span> </li>      <li>Take the entire dose <span class="Bold">within 15&nbsp;minutes</span>. If you cannot take the dose within 15&nbsp;minutes of preparing it, throw it away and prepare a new dose. Do not save it for use later.</li>     </ul> </li>    <li>If you miss a dose of ACIPHEX, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your normal schedule. Do not take 2&nbsp;doses at the same time. </li>    <li>If you take too much ACIPHEX, call your doctor or Poison Control Center right away, or go to the nearest hospital emergency room. </li>    <li>Your doctor may prescribe antibiotic medicines with ACIPHEX to help treat a stomach infection and heal stomach (duodenal) ulcers that are caused by bacteria called <span class="Italics">H.&nbsp;pylori</span>. Make sure you read the patient information that comes with an antibiotic before you start taking it.</li>   </ul>   <p> <span class="Bold">What are the possible side effects of ACIPHEX?</span> </p>   <p>ACIPHEX&nbsp;may cause serious side effects, including:</p>   <ul class="Disk">    <li> <span class="Bold">See &quot;What is the most important information I should know about ACIPHEX?&quot;</span> </li>    <li> <span class="Bold">V</span><span class="Bold">itamin B-12 deficiency. </span>ACIPHEX reduces the amount of acid in your stomach. Stomach acid is needed to absorb vitamin B-12 properly. Talk with your doctor about the possibility of vitamin B-12 deficiency if you have been on ACIPHEX for a long time (more than 3 years).</li>    <li> <span class="Bold">Low magnesium levels in your body.</span> This problem can be serious. Low magnesium can happen in some people who take a Proton Pump inhibitor (PPI) medicine for at least 3&nbsp;months. If low magnesium levels happen, it is usually after a year of treatment. You may or may not have symptoms of low magnesium.<br /> <br />Tell your doctor right away if you have any of these symptoms:     <ul class="Circle">      <li>seizures </li>      <li>dizziness </li>      <li>abnormal or fast heart beat </li>      <li>jitteriness </li>      <li>jerking movements or shaking (tremors) </li>      <li>muscle weakness </li>      <li>spasms of the hands and feet </li>      <li>cramps or muscle aches </li>      <li>spasm of the voice box</li>     </ul> <br />Your doctor may check the level of magnesium in your body before you start taking ACIPHEX, during treatment, or if you will be taking ACIPHEX for a long period of time.</li>   </ul>   <p>The most common side effects with ACIPHEX may include:</p>   <ul class="Disk">    <li>headache </li>    <li>pain </li>    <li>sore throat </li>    <li>gas </li>    <li>infection </li>    <li>constipation</li>   </ul>   <p>The most common side effects with ACIPHEX in children include:</p>   <ul class="Disk">    <li>stomach-area (abdomen) pain </li>    <li>diarrhea </li>    <li>headache</li>   </ul>   <p>Other side effects:</p>   <p> <span class="Bold">Serious allergic reactions.</span> Tell your doctor if you have any of the following symptoms with ACIPHEX:</p>   <ul class="Disk">    <li>rash </li>    <li>face swelling </li>    <li>throat tightness </li>    <li>difficulty breathing</li>   </ul>   <p>Your doctor may stop ACIPHEX if these symptoms happen.</p>   <p>Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the side effects of ACIPHEX. For more information, ask your doctor or pharmacist.</p>   <p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>   <p> <span class="Bold">How should I store ACIPHEX?</span> </p>   <ul class="Disk">    <li>Store ACIPHEX Tablets and ACIPHEX Sprinkle Delayed-Release Capsules in a dry place at room temperature between 68(F to 77&deg;F (20&deg;C to 25&deg;C).</li>   </ul>   <p> <span class="Bold">Keep ACIPHEX and all medicines out of the reach of children.</span> </p>   <p> <span class="Bold">General Information about ACIPHEX</span> </p>   <p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ACIPHEX for a condition for which it was not prescribed. Do not give ACIPHEX to other people, even if they have the same symptoms that you have. It may harm them.</p>   <p>This Medication Guide summarizes the most important information about ACIPHEX. If you would like more information, talk to your doctor. You can also ask your doctor or pharmacist for information about ACIPHEX that is written for healthcare professionals. For more information, go to http://www.aciphex.com/ or call 1-888-4-ACIPHEX.</p>   <p> <span class="Bold">What are the ingredients in ACIPHEX?</span> </p>   <p> <span class="Bold">Active ingredient:</span> rabeprazole sodium</p>   <p> <span class="Bold">ACIPHEX Delayed-Release Tablets inactive ingredients:</span> carnauba wax, crospovidone, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium stearate, mannitol, propylene glycol, sodium hydroxide, sodium stearyl fumarate, talc, and titanium dioxide. Iron oxide yellow is the coloring agent for the tablet coating. Iron oxide red is the ink pigment.</p>   <p> <span class="Bold">ACIPHEX Sprinkle Delayed-Release Capsules inactive ingredients:</span> colloidal silicon dioxide, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium oxide, magnesium stearate, mannitol, talc, titanium dioxide, carrageenan, potassium chloride, FD&amp;C Blue No.2 Aluminum Lake (in the 5&nbsp;mg capsule), FD&amp;C Yellow, No.&nbsp;6 (in the 10&nbsp;mg capsule), and gray printing ink.</p>   <p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>   <p>AcipHex Sprinkle is Distributed by FSC Laboratories, Inc., Charlotte, NC 28210.</p>   <p>Revised&nbsp;December 2014</p>   <p>ACIPHEX<span class="Sup">&reg;</span> is a registered trademark of Eisai R&amp;D Management Co., Ltd; ACIPHEX<span class="Sup">&reg;</span> Sprinkle™ is a trademark of Eisai R&amp;D Management Co., Ltd, each of which is licensed to Eisai Inc. All brand names are the trademarks of their respective owners.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="LINK_71ddde09-ef56-485f-8e83-39a630a7361e"></a>  <a name="section-18"></a>   <p></p>   <h1></h1>   <p class="First"> <span class="Bold">PRINCIPAL DISPLAY PANEL - 20 MG DELAYED-RELEASE TABLET</span> </p>   <p>NDC 62856-243-30</p>   <p>Rx only</p>   <p>AcipHex<span class="Sup">&reg;</span> <br />rabeprazole sodium<br />delayed-release<br />tablets</p>   <p>20 mg<br />30 tablets</p>   <div class="Figure">    <img src="image.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&name=aciphex%2D6%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 20 MG DELAYED-RELEASE TABLET NDC 62856-243-30 Rx only AcipHex&reg; rabeprazole sodium delayed-release tablets 20 mg 30 tablets" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>ACIPHEX&nbsp; </strong> <br /> <span class="contentTableReg">rabeprazole sodium tablet, delayed release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:62856-243</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>RABEPRAZOLE SODIUM</strong> (UNII: 3L36P16U4R) (RABEPRAZOLE - UNII:32828355LL)</td>          <td class="formItem">RABEPRAZOLE SODIUM</td>          <td class="formItem">20&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>CARNAUBA WAX</strong> (UNII: R12CBM0EIZ)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>CROSPOVIDONE</strong> (UNII: 68401960MK)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ETHYLCELLULOSES</strong> (UNII: 7Z8S9VYZ4B)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</strong> (UNII: 87Y6436BKR)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>MANNITOL</strong> (UNII: 3OWL53L36A)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>PROPYLENE GLYCOL</strong> (UNII: 6DC9Q167V3)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>SODIUM HYDROXIDE</strong> (UNII: 55X04QC32I)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>SODIUM STEARYL FUMARATE</strong> (UNII: 7CV7WJK4UI)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>TALC</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong> (UNII: RFW2ET671P)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">YELLOW (yellow)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">ROUND (ROUND)</td>          <td class="formLabel">Size</td>          <td class="formItem">8mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">ACIPHEX;20</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:62856-243-41</td>          <td class="formItem">100 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">1 in 1 BLISTER PACK; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:62856-243-30</td>          <td class="formItem">30 in 1 BOTTLE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:62856-243-90</td>          <td class="formItem">90 in 1 BOTTLE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA020973</td>          <td class="formItem">08/19/1999</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Eisai Inc. (831600833) </td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                                                                                    <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22RABEPRAZOLE%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=RABEPRAZOLE" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=RABEPRAZOLE" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=APRD01212&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">ACIPHEX- rabeprazole sodium tablet, delayed release <br></h3>            <h4>Number of versions: 10</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Jan 6, 2015</td>                        <td>							                                23                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=161612">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Oct 30, 2014</td>                        <td>							                                21                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=155857">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Oct 8, 2014</td>                        <td>							                                19                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=153590">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Sep 12, 2013</td>                        <td>							                                9                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=119125">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Mar 7, 2013</td>                        <td>							                                8                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=102132">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jun 6, 2012</td>                        <td>							                                6                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=80752">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jun 6, 2011</td>                        <td>							                                5                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=55870">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Mar 9, 2011</td>                        <td>							                                4                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=50197">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Mar 10, 2009</td>                        <td>							                                2                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=10184">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 3, 2008</td>                        <td>							                                1                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=9400">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">ACIPHEX- rabeprazole sodium tablet, delayed release <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=854868">854868</a></td>                              <td>RABEprazole sodium 20 MG Delayed Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=854868">854868</a></td>                              <td>Rabeprazole sodium 20 MG Delayed Release Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=854870">854870</a></td>                              <td>AcipHex 20 MG Delayed Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=854870">854870</a></td>                              <td>Rabeprazole sodium 20 MG Delayed Release Oral Tablet [Aciphex]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=854870">854870</a></td>                              <td>Aciphex 20 MG Delayed Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">ACIPHEX- rabeprazole sodium tablet, delayed release <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AACIPHEX%2D%20Rabeprazole%20Sodium%20Tablet%2C%20Delayed%20Release%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D5d103551%2D978f%2D472a%2D9c62%2D51e6e4dea068%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    